[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1149
1. Giannoukakis N, Phillips B, Trucco M: Toward a cure for type 1 diabetes mellitus: diabetes-suppressive dendritic cells and beyond. Pediatr Diabetes; 2008 Jun;9(3 Pt 2):4-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also, insulin does not eliminate the T1D hallmark: beta-cell-specific autoimmunity.
  • Criterion 2 has been partially realized using monoclonal antibodies specific for T-cell surface proteins.
  • Herein, we outline the current status of non-insulin-based therapies for T1D, with a focus on cell-based immunomodulation which we propose can achieve all three criteria illustrated above.


2. Park MJ, Taki T, Oda M, Watanabe T, Yumura-Yagi K, Kobayashi R, Suzuki N, Hara J, Horibe K, Hayashi Y: FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol; 2009 Apr;145(2):198-206
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma.
  • Mutation analysis of FBXW7 and NOTCH1 genes was performed in 55 T cell acute lymphoblastic leukaemia (T-ALL) and 14 T cell non-Hodgkin lymphoma (T-NHL) patients who were treated on the Japan Association of Childhood Leukaemia Study (JACLS) protocols ALL-97 and NHL-98.
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Gene Expression Regulation, Leukemic. Lymphoma, T-Cell / genetics. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics


3. Muramatsu H, Kojima S, Yoshimi A, Atsuta Y, Kato K, Nagatoshi Y, Inoue M, Koike K, Kawase T, Ito M, Kurosawa H, Tanizawa A, Tono C, Hamamoto K, Hotta N, Watanabe A, Morishima Y, Kawa K, Shimada H: Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Biol Blood Marrow Transplant; 2010 Feb;16(2):231-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: the Japan Marrow Donor Program.
  • Because of a small number of patients, only a few studies have addressed the outcome of bone marrow transplantation (BMT) in children with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), who receive graft from a volunteer-unrelated donor (VUD), especially after practical application of imatinib mesylate.
  • The probabilities of 5-year overall survival (OS) and leukemia-free survival (LFS) were 59.3% and 55.5%, respectively.
  • Multivariate analysis identified the following unfavorable survival factors: infused total nucleated cell dose<314 x 10(6) /kg (relative risk [RR]=2.43; 95% confidence interval [CI]=1.33-4.44; P=.004), advanced phase (RR=2.43; 95% CI=1.37-4.31; P=.004), and no major cytogenetic response (MCyR) at the time of BMT (RR=6.55; 95% CI=1.98-21.6; P=.002).
  • Disease phase, infused total nucleated cell dose, and cytogenetic response were independent risk factors for survival of unrelated BMT.
  • These findings provide important information for assessing the indications for and improving outcome in unrelated BMT for the treatment of pediatric CML.
  • [MeSH-major] Bone Marrow. Bone Marrow Transplantation. Hematopoietic Stem Cell Transplantation. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • (PMID = 19800016.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


Advertisement
4. Gururangan S, Chi SN, Young Poussaint T, Onar-Thomas A, Gilbertson RJ, Vajapeyam S, Friedman HS, Packer RJ, Rood BN, Boyett JM, Kun LE: Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol; 2010 Jun 20;28(18):3069-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):309-16 [18337733.001]
  • [Cites] Neuro Oncol. 2008 Aug;10(4):624-30 [18539884.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):383-9 [18793954.001]
  • [Cites] Pediatr Blood Cancer. 2008 Dec;51(6):806-11 [18802947.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6371-5 [18927275.001]
  • [Cites] J Neurooncol. 2009 Feb;91(3):329-36 [18953493.001]
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):740-5 [19114704.001]
  • [Cites] J Clin Oncol. 2009 Oct 1;27(28):4733-40 [19720927.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1878-86 [10766175.001]
  • [Cites] Oncogene. 2000 Nov 20;19(49):5598-605 [11114740.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(16):2064-72 [11597385.001]
  • [Cites] NMR Biomed. 2002 Feb;15(1):6-17 [11840548.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):237-53 [12187958.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4684-91 [12488414.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3542; author reply 3543 [12972536.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer. 1993 Jul 1;72(1):271-5 [8508417.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1516-25 [10334539.001]
  • [Cites] J Neurooncol. 1999 May;43(1):43-7 [10448870.001]
  • [Cites] Am J Health Syst Pharm. 2004 Nov 1;61(21 Suppl 5):S21-6 [15552623.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):172-87 [15687360.001]
  • [Cites] Neurol Res. 2005 Jun;27(4):371-7 [15949234.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2347-55 [15985545.001]
  • [Cites] Oncology. 2005;69 Suppl 3:25-33 [16301833.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1364-71 [16463390.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • (PMID = 20479404.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000188; United States / NCI NIH HHS / CA / U01 CA081457; United States / NCRR NIH HHS / RR / M01RR00188; United States / NCI NIH HHS / CA / U01CA81457
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0H43101T0J / irinotecan; 2S9ZZM9Q9V / Bevacizumab; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2903337
  •  go-up   go-down


5. Friedrich C, Schrum J, Chott A, Janka-Schaub G, Kabisch H: Ongoing remission after intensive ALL-type chemotherapy in pediatric intestinal T-cell lymphoma. Pediatr Blood Cancer; 2010 Apr;54(4):610-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ongoing remission after intensive ALL-type chemotherapy in pediatric intestinal T-cell lymphoma.
  • A rare case of primary intestinal T-cell lymphoma (ITL) of an 8-year-old boy is reported.
  • They showed monoclonal rearrangement of the T-cell receptor gamma-chain and no evidence of EBV infection.
  • Our patient remains in first remission 30 months after finishing the acute lymphoblastic leukemia protocol COALL-07-03 high risk standard.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Intestinal Neoplasms / drug therapy. Intestinal Neoplasms / pathology. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Child. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Methylprednisolone / administration & dosage. Neoplasm Staging. Receptors, Antigen, T-Cell, gamma-delta / genetics. Remission Induction. Thioguanine / administration & dosage. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20049930.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; FTK8U1GZNX / Thioguanine; X4W7ZR7023 / Methylprednisolone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


6. Fraser MO, Arslan M, Plant TM: Androgen and estrogen treatment, alone or in combination, differentially influences bone maturation and hypothalamic mechanisms that time puberty in the male rhesus monkey (Macaca mulatta). Pediatr Res; 2005 Jan;57(1):141-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Animals. Body Size / drug effects. Body Weight. Cell Proliferation. Dihydrotestosterone / pharmacology. Estradiol / pharmacology. Linear Models. Luteinizing Hormone / metabolism. Macaca mulatta. Male. Receptors, Androgen / metabolism. Sexual Maturation. Steroids / metabolism. Testosterone / pharmacology. Time Factors

  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15557106.001).
  • [ISSN] 0031-3998
  • [Journal-full-title] Pediatric research
  • [ISO-abbreviation] Pediatr. Res.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD13254; United States / NICHD NIH HHS / HD / U54 HD08610
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Estrogens; 0 / Receptors, Androgen; 0 / Steroids; 08J2K08A3Y / Dihydrotestosterone; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone
  •  go-up   go-down


7. Kwon YJ, Lee JW, Kim MS, Jang PS, Chung NG, Jeong DC, Kim YG, Han KJ, Lee SJ, Cho B, Kim HK: Cytogenetic analysis in childhood acute lymphoblastic leukemia: experience at a single institution in Korea. Int J Hematol; 2009 Mar;89(2):150-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic analysis in childhood acute lymphoblastic leukemia: experience at a single institution in Korea.
  • We evaluated major cytogenetic abnormalities associated with childhood acute lymphoblastic leukemia (ALL) through both fluorescent in situ hybridization and conventional chromosomal analysis for 132 ALL patients diagnosed at St Mary's Hospital in Korea.
  • Our study pool is representative of pediatric ALL patients in Korea as it consists of about 20% of patients diagnosed annually in Korea.
  • We believe that the data provided will aid in comparative studies of the treatment outcomes, as well as the type and incidence of chromosomal abnormalities associated with childhood ALL in various Asian nations and Western countries.
  • [MeSH-major] Chromosome Aberrations. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


8. Sangkhathat S, Kanngurn S, Jaruratanasirikul S, Tubtawee T, Chaiyapan W, Patrapinyokul S, Chiengkriwate P: Peripheral precocious puberty in a male caused by Leydig cell adenoma harboring a somatic mutation of the LHR gene: report of a case. J Med Assoc Thai; 2010 Sep;93(9):1093-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral precocious puberty in a male caused by Leydig cell adenoma harboring a somatic mutation of the LHR gene: report of a case.
  • A left orchiectomy was performed, and histopathology revealed a well-circumscribed Leydig cell tumor Molecular study of the exon 11 of the LHR gene revealed a missense mutation at the nucleotide position 1,732, leading to a substitution of histidine for aspartic acid at codon 578.
  • Interestingly, the substitution was consistent with all previously reported LHR alteration in pediatric Leydig cell adenoma, but which had never before been reported in male-limited precocious puberty, suggesting that the mutation is a molecular signature of the adenoma.
  • [MeSH-major] Leydig Cell Tumor / genetics. Mutation, Missense. Puberty, Precocious / genetics. Receptors, LH / genetics. Testicular Neoplasms / genetics


9. Peter A, Heiden T, Taube T, Körner G, Seeger K: Interphase FISH on TEL/AML1 positive acute lymphoblastic leukemia relapses--analysis of clinical relevance of additional TEL and AML1 copy number changes. Eur J Haematol; 2009 Nov;83(5):420-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interphase FISH on TEL/AML1 positive acute lymphoblastic leukemia relapses--analysis of clinical relevance of additional TEL and AML1 copy number changes.
  • OBJECTIVES: TEL/AML1 (ETV6/RUNX1) fusion resulting from the translocation t(12;21)(p13;q22) constitutes the most common chimeric fusion gene in initial childhood B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) (19-27%) and has been associated with good prognosis.
  • They also show that it is important to consider combined mutations in the analysis of this leukemia entity.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Dosage. In Situ Hybridization, Fluorescence. Interphase. Mutation. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19594616.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein
  •  go-up   go-down


10. Comoli P, Basso S, Zecca M, Pagliara D, Baldanti F, Bernardo ME, Barberi W, Moretta A, Labirio M, Paulli M, Furione M, Maccario R, Locatelli F: Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant; 2007 Jun;7(6):1648-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation.
  • The treatment of Epstein-Barr virus (EBV)-related post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation (HSCT) is still unsatisfactory.
  • We conducted a prospective trial to evaluate the impact of routine EBV surveillance and preemptive treatment with the anti-CD20 monoclonal antibody rituximab on the development of PTLD in pediatric recipients of extensively T-cell depleted HSCT from an HLA-haploidentical relative.
  • EBV-specific T-cell frequency, undetectable at time of EBV DNA positivity, was restored by T-cell therapy to levels comparable with controls.
  • [MeSH-major] Epstein-Barr Virus Infections / prevention & control. Lymphoproliferative Disorders / prevention & control. Stem Cell Transplantation / methods. T-Lymphocytes / immunology

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17511690.001).
  • [ISSN] 1600-6135
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / Antiviral Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


11. Ball LM, Bernardo ME, Roelofs H, Lankester A, Cometa A, Egeler RM, Locatelli F, Fibbe WE: Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood; 2007 Oct 1;110(7):2764-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation.
  • Haploidentical hematopoietic stem-cell transplantation (HSCT) is associated with an increased risk of graft failure.
  • [MeSH-major] Cell Culture Techniques / methods. Graft Rejection / prevention & control. Hematopoietic Stem Cell Transplantation. Lymphocytes / cytology. Lymphocytes / immunology. Mesenchymal Stem Cell Transplantation. Mesenchymal Stromal Cells / cytology
  • [MeSH-minor] Adolescent. Cell Proliferation. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Risk Factors

  • Genetic Alliance. consumer health - Transplantation.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638847.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Gokhale CD, Udipi SA, Ambaye RY, Pai SK, Advani SH: Post-therapy profile of serum total cholesterol, retinol and zinc in pediatric acute lymphoblastic leukemia and non-Hodgkin's lymphoma. J Am Coll Nutr; 2007 Feb;26(1):49-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-therapy profile of serum total cholesterol, retinol and zinc in pediatric acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
  • OBJECTIVE: To assess serum albumin, total cholesterol, retinol, zinc and hemoglobin in children who had completed treatment for acute lymphoblastic leukemia (ALL) and Non-Hodgkin's lymphoma (NHL).
  • [MeSH-major] Lymphoma, Non-Hodgkin / blood. Nutritional Status. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Trace Elements / blood. Vitamin A / blood. Vitamins / blood


13. Bratton SL, Van Duker H, Statler KD, Pulsipher MA, McArthur J, Keenan HT: Lower hospital mortality and complications after pediatric hematopoietic stem cell transplantation. Crit Care Med; 2008 Mar;36(3):923-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lower hospital mortality and complications after pediatric hematopoietic stem cell transplantation.
  • OBJECTIVE: To assess protective and risk factors for mortality among pediatric patients during initial care after hematopoietic stem cell transplantation (HSCT) and to evaluate changes in hospital mortality.
  • Compared with autologous HSCT, patients who received an allogenic HSCT without T-cell depletion were more likely to die (adjusted odds ratio, 2.4; 95% confidence interval, 1.5, 3.9), while children who received cord blood HSCT were at the greatest risk of hospital death (adjusted odds ratio, 4.8; 95% confidence interval, 2.6, 9.1).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hospital Mortality / trends

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Crit Care Med. 2008 Mar;36(3):1023-4 [18431315.001]
  • (PMID = 18091550.001).
  • [ISSN] 1530-0293
  • [Journal-full-title] Critical care medicine
  • [ISO-abbreviation] Crit. Care Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Sangkhathat S, Kusafuka T, Miao J, Yoneda A, Nara K, Yamamoto S, Kaneda Y, Fukuzawa M: In vitro RNA interference against beta-catenin inhibits the proliferation of pediatric hepatic tumors. Int J Oncol; 2006 Mar;28(3):715-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro RNA interference against beta-catenin inhibits the proliferation of pediatric hepatic tumors.
  • Mutations of beta-catenin have been identified in the majority of pediatric hepatic malignancies, including hepatoblastoma (HB) and hepatocellular carcinoma (HCC), suggesting its important contribution in hepatic tumorigenesis in this age group.
  • To address beta-catenin's capability in maintaining the malignant phenotype in established pediatric HB and HCC cell lines, HuH-6 and HepG2, harboring mutated and overexpressed beta-catenin, we carried out a series of in vitro analyses through a transfection of short interfering RNAs (siRNAs) to generate a loss-of-function model.
  • HuH-7, another HB cell line derived from a pediatric patient without a stabilizing mutation was used for comparison.
  • In all cell lines, beta-catenin mRNA was suppressed by 80-90% after 48 h of transfection, and a reduction of its protein expression was demonstrated.
  • The in vitro proliferation of both cell lines was transiently inhibited.
  • Our data indicate that beta-catenin can be considered a specific target for gene therapy in pediatric hepatic tumors with mutations and overexpression of this gene.
  • [MeSH-major] Cell Proliferation. RNA Interference. beta Catenin / genetics
  • [MeSH-minor] Apoptosis. Blotting, Western. Cell Line, Tumor. Cell Nucleus / metabolism. Child. DNA Mutational Analysis. Gene Expression Regulation, Neoplastic. Humans. Liver Neoplasms / genetics. Liver Neoplasms / pathology. Liver Neoplasms / physiopathology. Mutation. RNA, Small Interfering / genetics. Transfection

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465377.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / beta Catenin
  •  go-up   go-down


15. Korfei M, Fühlhuber V, Schmidt-Wöll T, Kaps M, Preissner KT, Blaes F: Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome. J Neuroimmunol; 2005 Dec 30;170(1-2):150-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional characterisation of autoantibodies from patients with pediatric opsoclonus-myoclonus-syndrome.
  • TUNEL assay revealed increased apoptotic cell death of the neuroblastoma cells after exposure to OMS IgG, but not to NB or control IgG (p<0.01).
  • These findings indicate that surface-binding autoantibodies are present in OMS patients and these autoantibodies cause inhibition of cell proliferation and induce apoptosis.
  • [MeSH-minor] Apoptosis / drug effects. Autoantigens / immunology. Blotting, Western. Case-Control Studies. Cell Death / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Separation. Child, Preschool. Female. Flow Cytometry. Fluorescent Antibody Technique, Indirect. Humans. Immunoglobulin G / immunology. Immunoglobulin G / pharmacology. Infant. Male

  • Genetic Alliance. consumer health - Dancing Eyes-Dancing Feet Syndrome.
  • Genetic Alliance. consumer health - Myoclonus.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203043.001).
  • [ISSN] 0165-5728
  • [Journal-full-title] Journal of neuroimmunology
  • [ISO-abbreviation] J. Neuroimmunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Autoantigens; 0 / Immunoglobulin G
  •  go-up   go-down


16. Jamroziak K, Robak T: Do polymorphisms in ABC transporter genes influence risk of childhood acute lymphoblastic leukemia? Leuk Res; 2008 Aug;32(8):1173-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do polymorphisms in ABC transporter genes influence risk of childhood acute lymphoblastic leukemia?
  • It is widely accepted that pathogenesis of childhood acute lymphoblastic leukemia (ALL) is related to the interplay between specific environmental exposure and inherited background.
  • Here, we review several recent reports on potential association between single nucleotide polymorphisms (SNPs) in genes encoding for ABC transporters with predisposition to pediatric ALL.
  • [MeSH-major] ATP-Binding Cassette Transporters / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Leuk Res. 2008 Aug;32(8):1214-20 [18243305.001]
  • (PMID = 18294687.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Comment
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters; 0 / ATP-Binding Cassette, Sub-Family B, Member 1
  •  go-up   go-down


17. Thobakgale CF, Prendergast A, Crawford H, Mkhwanazi N, Ramduth D, Reddy S, Molina C, Mncube Z, Leslie A, Prado J, Chonco F, Mphatshwe W, Tudor-Williams G, Jeena P, Blanckenberg N, Dong K, Kiepiela P, Coovadia H, Ndung'u T, Walker BD, Goulder PJ: Impact of HLA in mother and child on disease progression of pediatric human immunodeficiency virus type 1 infection. J Virol; 2009 Oct;83(19):10234-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of HLA in mother and child on disease progression of pediatric human immunodeficiency virus type 1 infection.
  • A broad Gag-specific CD8(+) T-cell response is associated with effective control of adult human immunodeficiency virus (HIV) infection.
  • In this study of pediatric infection, we tested the hypothesis that children may tend to progress relatively slowly if either they themselves possess one of the protective HLA-B alleles or the mother possesses one of these alleles, thereby transmitting a low-fitness virus to the child.
  • We analyzed HLA type, CD8(+) T-cell responses, and viral sequence changes for 61 mother-child pairs from Durban, South Africa, who were monitored from birth.
  • Slow progressors tended to make CD8(+) T-cell responses to Gag epitopes presented by the protective HLA-B alleles, in contrast to progressors expressing the same alleles (P = 0.07; Fisher's exact test).
  • These data show that HLA class I alleles influence disease progression in pediatric as well as adult infection, both as a result of the CD8(+) T-cell responses generated in the child and through the transmission of low-fitness viruses by the mother.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Virol. 2015 Aug;89(15):8101 [26157156.001]
  • [Cites] J Exp Med. 2008 May 12;205(5):1009-17 [18426987.001]
  • [Cites] AIDS. 2008 Jul 11;22(11):1333-43 [18580613.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):68-80 [17617274.001]
  • [Cites] AIDS. 2007 Jun 19;21(10):1253-61 [17545701.001]
  • [Cites] J Virol. 2005 Sep;79(17):11529-32 [16103206.001]
  • [Cites] J Infect Dis. 2008 Jan 15;197(2):300-8 [18177249.001]
  • [Cites] J Virol. 2009 Sep;83(17):8616-27 [19515764.001]
  • [Cites] J Immunol. 2005 Jun 15;174(12):7524-30 [15944251.001]
  • [Cites] Immunol Lett. 2001 Nov 1;79(1-2):109-16 [11595297.001]
  • [Cites] J Exp Med. 2004 Jun 21;199(12):1709-18 [15210746.001]
  • [Cites] Nature. 2001 Jul 19;412(6844):334-8 [11460164.001]
  • [Cites] J Virol. 2007 Aug;81(15):8346-51 [17507468.001]
  • [Cites] AIDS. 2004 Jun 18;18(9):1281-9 [15362660.001]
  • [Cites] Science. 1996 Nov 8;274(5289):1010-1 [17798610.001]
  • [Cites] Lancet. 2003 Sep 13;362(9387):859-68 [13678973.001]
  • [Cites] J Virol. 2004 Aug;78(16):8927-30 [15280502.001]
  • [Cites] AIDS. 2009 Mar 27;23(6):679-88 [19279442.001]
  • [Cites] J Virol. 2008 Sep;82(17):8548-59 [18596105.001]
  • [Cites] PLoS Pathog. 2008 Mar;4(3):e1000033 [18369479.001]
  • [Cites] Nat Med. 2004 Mar;10(3):282-9 [14770175.001]
  • [Cites] Br Med Bull. 2001;58:89-108 [11714626.001]
  • [Cites] Nat Rev Immunol. 2008 Aug;8(8):619-30 [18617886.001]
  • [Cites] J Virol. 2006 Apr;80(7):3617-23 [16537629.001]
  • [Cites] Nat Med. 2007 Jan;13(1):46-53 [17173051.001]
  • [Cites] Nat Genet. 2007 Jun;39(6):708-10 [17534364.001]
  • [Cites] Lancet. 1999 Sep 4;354(9181):795-802 [10485720.001]
  • [Cites] J Virol. 2007 Dec;81(23):12775-84 [17881456.001]
  • [Cites] J Virol. 2006 Mar;80(6):3122-5 [16501126.001]
  • [Cites] J Virol. 2007 Mar;81(5):2440-8 [17182686.001]
  • [Cites] J Virol. 2007 Nov;81(22):12608-18 [17728232.001]
  • [Cites] Nature. 2009 Apr 2;458(7238):641-5 [19242411.001]
  • [Cites] J Virol. 2005 Sep;79(18):12100-5 [16140787.001]
  • [Cites] Nature. 2004 Dec 9;432(7018):769-75 [15592417.001]
  • [Cites] J Virol. 2008 Jun;82(11):5594-605 [18385228.001]
  • (PMID = 19605475.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0500384; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epitopes; 0 / Gene Products, gag; 0 / HLA Antigens; 0 / HLA-B Antigens
  • [Other-IDs] NLM/ PMC2748050
  •  go-up   go-down


18. Medhi K, Kumar R, Rishi A, Kumar L, Bakhshi S: Subcutaneous panniculitislike T-cell lymphoma with hemophagocytosis: complete remission with BFM-90 protocol. J Pediatr Hematol Oncol; 2008 Jul;30(7):558-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous panniculitislike T-cell lymphoma with hemophagocytosis: complete remission with BFM-90 protocol.
  • SUMMARY: Subcutaneous panniculitislike T-cell lymphoma (SPTCL) is an uncommon type of cutaneous lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphohistiocytosis, Hemophagocytic / etiology. Lymphoma, T-Cell, Cutaneous / complications. Panniculitis / etiology

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18797207.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


19. Seegmiller AC, Kroft SH, Karandikar NJ, McKenna RW: Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia. Am J Clin Pathol; 2009 Dec;132(6):940-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of immunophenotypic aberrancies in 200 cases of B acute lymphoblastic leukemia.
  • Morphologic distinction of leukemic lymphoblasts in B acute lymphoblastic leukemia (B-ALL) from their nonneoplastic counterparts in bone marrow (hematogones) can be difficult.
  • Of 200 cases, 9.0% aberrantly expressed T cell-associated antigens.
  • There were significant differences in antigen-expression patterns between adult and pediatric B-ALL.
  • [MeSH-major] Bone Marrow Cells / pathology. Immunophenotyping / methods. Leukemia, Lymphocytic, Chronic, B-Cell / pathology. Precursor Cells, B-Lymphoid / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19926587.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


20. Forestier E, Izraeli S, Beverloo B, Haas O, Pession A, Michalová K, Stark B, Harrison CJ, Teigler-Schlegel A, Johansson B: Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. Blood; 2008 Feb 1;111(3):1575-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study.
  • Children with Down syndrome (DS) have a markedly increased risk of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
  • Unlike previous smaller series, a significant proportion of DS-ALLs had the typical B-cell precursor ALL abnormalities high hyperdiploidy (HeH; 11%) and t(12;21)(p13;q22) (10%).
  • [MeSH-major] Down Syndrome / complications. Down Syndrome / genetics. Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


21. Kawahara I, Masui K, Horie N, Matsuo T, Kitagawa N, Tsutsumi K, Nagata I, Morikawa M, Hayashi T: Radiation-induced meningioma following prophylactic radiotherapy for acute lymphoblastic leukemia in childhood. Pediatr Neurosurg; 2007;43(1):36-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced meningioma following prophylactic radiotherapy for acute lymphoblastic leukemia in childhood.
  • BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy.
  • CONCLUSION: Long-term survivors who received radiotherapy for ALL in childhood are at risk for late complications, including radiation-induced meningioma.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / etiology. Meningioma / diagnosis. Meningioma / etiology. Neoplasms, Radiation-Induced / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy


22. Saglani S, Malmström K, Pelkonen AS, Malmberg LP, Lindahl H, Kajosaari M, Turpeinen M, Rogers AV, Payne DN, Bush A, Haahtela T, Mäkelä MJ, Jeffery PK: Airway remodeling and inflammation in symptomatic infants with reversible airflow obstruction. Am J Respir Crit Care Med; 2005 Apr 1;171(7):722-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Group D: 17 children, median age 10.3 years (6-16 years), with difficult asthma; Group E: 10 pediatric control subjects without asthma, median age 10 years (6-16 years); and Group F: nine adult normal, healthy control subjects, median age 27 years (21-42 years).
  • MAIN RESULTS: There were no significant differences in RBM thickness or inflammatory cell number between the infant groups.


23. Hazra R, Gafni RI, Maldarelli F, Balis FM, Tullio AN, DeCarlo E, Worrell CJ, Steinberg SM, Flaherty J, Yale K, Kearney BP, Zeichner SL: Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics; 2005 Dec;116(6):e846-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.
  • Tenofovir disoproxil fumarate (DF) is a promising agent for use in pediatric salvage therapy, because of its tolerability, efficacy, and resistance profile.
  • We designed this study to provide preliminary pediatric safety and dosing information on tenofovir DF, while also providing potentially efficacious salvage therapy for heavily treatment-experienced, HIV-infected children.
  • The overall median increases in CD4+ T cell counts were 58 cells per mm3 (range: -64 to 589 cells per mm3) at week 24 and 0 cells per mm3 (range: -274 to 768 cells per mm3) at week 48.
  • The CD4+ cell responses among the virologic responders were high and sustained.


24. Scheifele DW, Ochnio JJ, Halperin SA: Cellular immunity as a potential cause of local reactions to booster vaccination with diphtheria and tetanus toxoids and acellular pertussis antigens. Pediatr Infect Dis J; 2009 Nov;28(11):985-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cell-mediated immunity (CMI) develops after primary DTaP vaccination and might contribute to local reactions to booster doses, a possibility explored in this study.
  • [MeSH-minor] Animals. Antigens, Bacterial / immunology. Cell Proliferation. Cells, Cultured. Child, Preschool. Cytokines / secretion. Diphtheria / immunology. Diphtheria / prevention & control. Female. Humans. Leukocytes, Mononuclear / immunology. Male. Tetanus / immunology. Tetanus / prevention & control. Whooping Cough / immunology. Whooping Cough / prevention & control

  • Genetic Alliance. consumer health - Diphtheria.
  • Genetic Alliance. consumer health - Tetanus.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Tetanus, Diphtheria, and Pertussis Vaccines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755930.001).
  • [ISSN] 1532-0987
  • [Journal-full-title] The Pediatric infectious disease journal
  • [ISO-abbreviation] Pediatr. Infect. Dis. J.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Cytokines; 0 / Diphtheria-Tetanus-acellular Pertussis Vaccines
  •  go-up   go-down


25. Holmqvist AS, Wiebe T, Hjorth L, Lindgren A, Øra I, Moëll C: Young age at diagnosis is a risk factor for negative late socio-economic effects after acute lymphoblastic leukemia in childhood. Pediatr Blood Cancer; 2010 Oct;55(4):698-707
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Young age at diagnosis is a risk factor for negative late socio-economic effects after acute lymphoblastic leukemia in childhood.
  • BACKGROUND: The increasing number of survivors after childhood cancer requires characterization of the late complications of these diseases and their treatment.
  • We examined a large number of possible socio-economic late effects following treatment for acute lymphoblastic leukemia (ALL) in order to identify factors leading to a poor outcome.
  • CONCLUSIONS: Young age at diagnosis, as well as treatment with cranial irradiation, is a risk factor for socio-economic late effects after treatment for ALL in childhood.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


26. Kawamata N, Ogawa S, Zimmermann M, Niebuhr B, Stocking C, Sanada M, Hemminki K, Yamatomo G, Nannya Y, Koehler R, Flohr T, Miller CW, Harbott J, Ludwig WD, Stanulla M, Schrappe M, Bartram CR, Koeffler HP: Cloning of genes involved in chromosomal translocations by high-resolution single nucleotide polymorphism genomic microarray. Proc Natl Acad Sci U S A; 2008 Aug 19;105(33):11921-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using this technique, we found that the PAX5 gene was rearranged to a variety of partner genes including ETV6, FOXP1, AUTS2, and C20orf112 in pediatric acute lymphoblastic leukemia (ALL).
  • In human B cell leukemia cells, binding of wild-type PAX5 to a regulatory region of BLK, one of the direct downstream target genes of PAX5, was diminished by expression of the PAX5-fusion protein, leading to repression of BLK.
  • [MeSH-minor] Animals. B-Cell-Specific Activator Protein / genetics. B-Cell-Specific Activator Protein / metabolism. Base Sequence. Cell Line. Cloning, Molecular. DNA / genetics. Humans. Mice. Molecular Sequence Data. Oligonucleotide Array Sequence Analysis. Transcription, Genetic / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8337-41 [16951139.001]
  • [Cites] Immunity. 2006 Mar;24(3):269-81 [16546096.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3417-23 [17179230.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Blood. 2007 May 1;109(9):3697-705 [17218387.001]
  • [Cites] Am J Hum Genet. 2007 Jul;81(1):114-26 [17564968.001]
  • [Cites] Immunity. 2007 Jul;27(1):49-63 [17658281.001]
  • [Cites] Br J Haematol. 2007 Oct;139(2):269-74 [17897302.001]
  • [Cites] Blood. 2008 Jan 15;111(2):776-84 [17890455.001]
  • [Cites] Cancer. 2008 Mar 15;112(6):1296-305 [18246537.001]
  • [Cites] Cell. 2008 Mar 21;132(6):929-34 [18358806.001]
  • [Cites] Nat Biotechnol. 2000 Sep;18(9):1001-5 [10973224.001]
  • [Cites] Semin Hematol. 2000 Oct;37(4):334-47 [11071356.001]
  • [Cites] J Immunol. 2001 Jun 1;166(11):6704-10 [11359826.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4666-70 [11406533.001]
  • [Cites] Nature. 2001 Jul 19;412(6844):341-6 [11460166.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1532-42 [12176867.001]
  • [Cites] J Exp Med. 2002 Nov 4;196(9):1227-40 [12417632.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):89-101 [12563308.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Cell. 2004 May 28;117(5):663-76 [15163413.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23):8998-9002 [2461560.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5695-9 [8202550.001]
  • [Cites] Cell. 1994 Dec 2;79(5):901-12 [8001127.001]
  • [Cites] J Biol Chem. 1995 Oct 27;270(43):25968-75 [7592787.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):6129-34 [8650231.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4110-7 [8943844.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):375-8 [15695375.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6071-9 [16024607.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Blood. 2007 Jan 1;109(1):281-9 [16968900.001]
  • (PMID = 18697940.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EU784145/ EU784146/ EU784147/ EU784148
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / PAX5 protein, human; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC2575257
  •  go-up   go-down


27. Kiss F, Buslig J, Szegedi I, Scholtz B, Kappelmayer J, Kiss C: Early relapse after rituximab chemoimmunotherapy. Pediatr Blood Cancer; 2008 Feb;50(2):372-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In relapsed/refractory childhood acute lymphoblastic leukemia (ALL) of the B-cell lineage rituximab, a monoclonal anti-CD20 antibody was used successfully in some cases.
  • We report on a 15-year-old female with relapsed CD20-positive B-cell progenitor ALL treated with rituximab because of positive minimal residual disease signals after chemotherapy, as checked by flow cytometry and real time quantitative-PCR.
  • The patient died with fulminant aspergillosis before hematopoietic stem cell transplantation could be performed.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Flow Cytometry. Gene Rearrangement, delta-Chain T-Cell Antigen Receptor. Humans. Neoplasm, Residual / pathology. Recurrence. Rituximab

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17973316.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


28. Kwiecińska K, Balwierz W, Moryl-Bujakowska A, Wachowiak J, Derwich K, Matysiak M, Pawelec K, Chybicka A, Dobaczewski G, Kowalczyk JR, Wiśniewska-Slusarz H, Sońta-Jakimczyk D, Szczepański T, Tomaszewska R, Wysocki M, Styczyński J, Balcerska A, Płoszyńska A: [Long-term observations of children with acute lymphoblastic leukemia and high leukocytosis treated according to modified "New York" protocols (1987-2003)]. Przegl Lek; 2010;67(6):350-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term observations of children with acute lymphoblastic leukemia and high leukocytosis treated according to modified "New York" protocols (1987-2003)].
  • Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy.
  • We present the treatment results of 340 children with ALL treated in nine centers of Polish Pediatric Leukemia/Lymphoma Study Group (PPLLSG) according to three consecutive versions of modified "New York" protocol (group I, II, and III) between 1987 and 2003.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukocytosis / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21344760.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Poland
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; EC 3.5.1.1 / Asparaginase; FTK8U1GZNX / Thioguanine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; New York protocol
  •  go-up   go-down


29. Muñoz A, Olivé T, Martinez A, Bureo E, Maldonado MS, Diaz de Heredia C, Sastre A, Gonzalez-Vicent M, Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON): Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON). Pediatr Hematol Oncol; 2007 Sep;24(6):393-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
  • Allogeneic stem cell transplantation is the only curative treatment for Wiskott-Aldrich syndrome.
  • GvHD prophylaxis consisted of cyclosporine and methotrexate in most patients plus T-cell depletion in the haploidentical HSCT.
  • Four patients died, 2 transplanted from matched donors (1 from acute GvHD and organ failure, 1 from a lymphoproliferative disorder after a second transplant), and 2 transplanted from mismatched unrelated donors (1 from acute GvHD and organ failure, 1 from graft failure and infection).
  • Allogeneic hemopoietic stem cell transplantation must be utilized in all patients with severe Wisckott-Aldrich syndrome, using the most suitable graft variant for each patient.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / statistics & numerical data. Wiskott-Aldrich Syndrome / surgery

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Wiskott Aldrich syndrome.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. BUSULFAN .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710656.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / HLA Antigens; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; G1LN9045DK / Busulfan; P2K93U8740 / fludarabine; Q41OR9510P / Melphalan
  •  go-up   go-down


30. Shalapour S, Zelmer A, Pfau M, Moderegger E, Costa-Blechschmidt C, van Landeghem FK, Taube T, Fichtner I, Bührer C, Henze G, Seeger K, Wellmann S: The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo. Clin Cancer Res; 2006 Sep 15;12(18):5526-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo.
  • PURPOSE: Thalidomide and its analogues have shown promise in the treatment of multiple myeloma but their therapeutic potential has not been evaluated in models of acute lymphoblastic leukemia (ALL).
  • EXPERIMENTAL DESIGN: We assessed the effects of the thalidomide analogue, CC-4047, on the growth and apoptosis signaling of human B cell precursor (BCP) ALL cell lines and freshly obtained childhood BCP-ALL cells grown with or without stromal cells.
  • RESULTS: CC-4047 reduced the proliferation of human BCP-ALL cell lines in vitro.
  • In contrast with the antileukemic effect of cytarabin, this was more pronounced when cell lines or freshly obtained childhood BCP-ALL cells were cocultured with stromal cells.
  • The inhibition of tumor growth, caspase-3 cleavage, and reduced microvessel density was observed in nonobese diabetic/severe combined immunodeficiency mice inoculated s.c. with childhood BCP-ALL cells upon CC-4047 treatment.
  • [MeSH-major] Apoptosis / drug effects. Cell Proliferation / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Thalidomide / analogs & derivatives

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000689.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; D2UX06XLB5 / pomalidomide; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


31. Schotte D, Chau JC, Sylvester G, Liu G, Chen C, van der Velden VH, Broekhuis MJ, Peters TC, Pieters R, den Boer ML: Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. Leukemia; 2009 Feb;23(2):313-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia.
  • To identify miRNAs relevant to pediatric acute lymphoblastic leukemia (ALL), we cloned 105 known and 8 new miRNA genes expressed in patients' leukemia cells.
  • Eight miRNAs were differentially expressed between MLL and non-MLL precursor B-ALL cases (P<0.05).
  • Most remarkably, miR-708 was 250- up to 6500-fold higher expressed in 57 TEL-AML1, BCR-ABL, E2A-PBX1, hyperdiploid and B-other cases than in 20 MLL-rearranged and 15 T-ALL cases (0.0001<P<0.01), whereas the expression of miR-196b was 500-fold higher in MLL-rearranged and 800-fold higher in 5 of 15 T-ALL cases as compared with the expression level in the remaining precursor B-ALL cases (P<0.001).
  • The expression did not correlate with the maturation status of leukemia cells based on immunoglobulin and T-cell receptor rearrangements, immunophenotype or MLL-fusion partner.
  • [MeSH-major] MicroRNAs / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. RNA, Neoplasm / genetics
  • [MeSH-minor] Cloning, Molecular. Gene Expression Regulation, Neoplastic. Humans. Infant. Infant, Newborn. Myeloid-Lymphoid Leukemia Protein / genetics


32. Kennedy-Nasser AA, Bollard CM, Myers GD, Leung KS, Gottschalk S, Zhang Y, Liu H, Heslop HE, Brenner MK, Krance RA: Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant; 2008 Nov;14(11):1245-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen.
  • HLA-matched sibling donor (MSD) stem cell transplantation can cure>60% of pediatric patients with acute lymphoblastic leukemia (ALL), but <30% of patients will have a sibling donor.
  • The addition of alemtuzumab (Campath 1-H) to AD transplants produces in vivo T cell depletion, which may reduce the risk for GVHD.
  • We now report the outcome for 83 children with ALL (41 MSD, 42 AD) undergoing stem cell transplantation in first or second complete remission.
  • For children undergoing stem cell transplantation (SCT) from alternative donors, alemtuzumab with a myeloablative conditioning regimen resulted in DFS comparable to MSD.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antibodies, Neoplasm / administration & dosage. Antineoplastic Agents / administration & dosage. Donor Selection. Hematopoietic Stem Cell Transplantation. Living Donors. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Siblings. Transplantation Conditioning

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18940679.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab
  •  go-up   go-down


33. Rocha V, Locatelli F: Searching for alternative hematopoietic stem cell donors for pediatric patients. Bone Marrow Transplant; 2008 Jan;41(2):207-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Searching for alternative hematopoietic stem cell donors for pediatric patients.
  • The use of alternative hematopoietic stem cell (HSC) donors has been witnessing important progress, mainly due to: (i) better HLA matching at the allelic level between donor and recipient in unrelated HSC transplantation (HSCT) translating into better patient outcome;.
  • (ii) better donor choice and patient selection in unrelated, often HLA-mismatched, cord blood transplantation and (iii) new strategies of adoptive cell therapy aimed at improving the results of T-cell-depleted haploidentical HSCT from a relative.
  • Therefore, any physician has to carefully evaluate, for each single pediatric patient in need of an allograft, all the possible alternatives to choose the best HSC donor, taking into account type of disease to be treated, urgency of transplantation, donor characteristics and center's experience.
  • This review will analyze in detail the advantages and limitations of each of the three options of alternative donor HSCT and the main criteria to be used for choosing the most suitable donor for pediatric patients lacking an HLA-identical sibling.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Histocompatibility Testing. Tissue Donors
  • [MeSH-minor] Child, Preschool. Cord Blood Stem Cell Transplantation. Graft vs Host Disease. Humans. Lymphocyte Depletion. Survival Analysis. Transplantation, Homologous / adverse effects. Transplantation, Homologous / methods

  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18084331.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 52
  •  go-up   go-down


34. Drewa T, Wolski Z, Misterek B, Debski R, Styczynski J: The influence of alpha1-antagonist on the expression pattern of TNF receptor family in primary culture of prostate epithelial cells from BPH patients. Prostate Cancer Prostatic Dis; 2008;11(1):88-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A decrease of CD40-positive cell population was observed in the lowest concentration.

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17533395.001).
  • [ISSN] 1476-5608
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Antigens, CD40; 0 / Antigens, CD95; 0 / Receptors, Tumor Necrosis Factor, Type I; 0 / Receptors, Tumor Necrosis Factor, Type II; NW1291F1W8 / Doxazosin
  •  go-up   go-down


35. Lang P, Mueller I, Greil J, Bader P, Schumm M, Pfeiffer M, Hoelle W, Klingebiel T, Heinzelmann F, Belka C, Schlegel PG, Kremens B, Woessmann W, Handgretinger R: Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients. Blood Cells Mol Dis; 2008 Jan-Feb;40(1):33-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients.
  • We report a cohort of 11 pediatric patients with leukemias (n=8) and severe aplastic anemia (n=3) who experienced graft rejection after myeloablative transplantation from mismatched related donors (n=6) or after cord blood or matched unrelated donor transplantation (n=5).
  • [MeSH-major] Graft Rejection. Hematopoietic Stem Cell Transplantation / methods. Histocompatibility
  • [MeSH-minor] Adolescent. Adult. Cause of Death. Cell Count. Cell Separation. Child. Child, Preschool. Cohort Studies. Disease-Free Survival. Graft Survival. Haplotypes. Humans. Leukocyte Reduction Procedures. Reoperation. Transplantation Chimera. Transplantation Conditioning / methods. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17884640.001).
  • [ISSN] 1079-9796
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


36. Zangwill SD, Ellis TM, Zlotocha J, Jaquiss RD, Tweddell JS, Mussatto KA, Berger S: The virtual crossmatch--a screening tool for sensitized pediatric heart transplant recipients. Pediatr Transplant; 2006 Feb;10(1):38-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The virtual crossmatch--a screening tool for sensitized pediatric heart transplant recipients.
  • Using recipient serum, direct-flow cytometric T- and B-cell XM were run for potential donors against whose HLA type the recipient had specific antibodies (group 1, n = 7) and for potential donors with predicted compatible HLA types by virtual XM (group 2, n = 7).
  • A positive T-cell XM was defined as MCD > 50, whereas MCD > 100 constituted a positive B-cell result.
  • The rate of T-cell reactivity was significantly less in group 2 than in group 1 (29% vs. 100%, p = 0.02); similarly, B-cell reactivity was also less for group 2 (14% vs. 100%, p = 0.005).
  • Although only 72% specific in predicting a negative T-cell XM, and 86% specific for negative B-cell XM, the false negatives were weakly positive and would probably have been clinically acceptable.

  • Genetic Alliance. consumer health - Heart Transplant.
  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16499585.001).
  • [ISSN] 1397-3142
  • [Journal-full-title] Pediatric transplantation
  • [ISO-abbreviation] Pediatr Transplant
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


37. Oschlies I, Salaverria I, Mahn F, Meinhardt A, Zimmermann M, Woessmann W, Burkhardt B, Gesk S, Krams M, Reiter A, Siebert R, Klapper W: Pediatric follicular lymphoma--a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin's Lymphoma--Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials. Haematologica; 2010 Feb;95(2):253-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric follicular lymphoma--a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin's Lymphoma--Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials.
  • Background Pediatric follicular lymphoma has recently been recognized as a novel variant of follicular lymphoma in the World Health Organization classification of lymphomas.
  • DESIGN AND METHODS: We analyzed 25 cases of pediatric follicular lymphoma (patients aged <or=18 years) by morphology, immunohistochemistry and interphase fluorescence in situ hybridization.
  • RESULTS: The genetic hallmark of adult follicular lymphoma, t(14;18)(q32;q21), was not detectable in any of the pediatric cases, although BCL2 protein was expressed in 55% of the latter cases.
  • Patients with pediatric follicular lymphoma had long event-free survival and, in contrast to adult follicular lymphoma, the clinical course was not dominated by relapses.
  • A simultaneous diffuse large B-cell lymphoma was frequently detected at initial diagnosis in children but did not indicate an aggressive clinical course.
  • Conclusions Our data suggest that pediatric follicular lymphoma is a disease that differs from its adult counterpart both genetically and clinically.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cohort Studies. Cytogenetic Analysis. Female. Gene Expression. Humans. Immunohistochemistry. Infant. Lymphoma, Large B-Cell, Diffuse / diagnosis. Male. Proto-Oncogene Proteins c-bcl-2 / genetics. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]
  • [Cites] Br J Haematol. 2008 Jun;142(2):166-78 [18492111.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Blood. 2004 Aug 1;104(3):626-33 [14982884.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2667-74 [15238420.001]
  • [Cites] Cancer. 1979 Apr;43(4):1216-24 [376087.001]
  • [Cites] Semin Oncol. 1980 Sep;7(3):332-9 [7414342.001]
  • [Cites] Cancer. 1981 Nov 15;48(10):2223-35 [7028244.001]
  • [Cites] Mod Pathol. 1990 May;3(3):308-13 [2194214.001]
  • [Cites] Leukemia. 1992 Aug;6(8):761-5 [1640726.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):359-72 [7844597.001]
  • [Cites] Br J Haematol. 1998 Oct;103(1):220-3 [9792312.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1626-35 [10193956.001]
  • [Cites] Blood. 2005 Feb 1;105(3):948-58 [15486066.001]
  • [Cites] Am J Clin Pathol. 2004 Dec;122 Suppl:S98-109 [15690646.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):141-51 [16645199.001]
  • [Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]
  • [Cites] J Clin Oncol. 2007 Jun 10;25(17):2426-33 [17485708.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1374-81 [18509088.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5165-9 [18838711.001]
  • [Cites] Int J Cancer. 2009 Feb 15;124(4):958-63 [19030176.001]
  • [Cites] Arch Pathol Lab Med. 2009 Jan;133(1):142-6 [19123728.001]
  • [Cites] Br J Haematol. 2008 Jul;142(3):329-47 [18537979.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1959-64 [11877266.001]
  • (PMID = 19679882.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  • [Other-IDs] NLM/ PMC2817028
  •  go-up   go-down


38. Savoldo B, Rooney CM, Quiros-Tejeira RE, Caldwell Y, Wagner HJ, Lee T, Finegold MJ, Dotti G, Heslop HE, Goss JA: Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant; 2005 Mar;5(3):566-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The evaluation of long-term cellular immunity to EBV in pediatric orthotopic liver transplant (OLT) recipients after treatment with the humanized anti-CD20 monoclonal antibody (Rituximab) has not yet been explored.
  • Their frequency of EBV-specific T-cell precursors, measured by Elispot analysis, remained lower than in healthy controls.
  • However, EBV-specific T-cell immunocompetence, which may be crucial for the long-term control of EBV-mediated proliferation, did not improve.

  • Genetic Alliance. consumer health - Liver Disease.
  • Genetic Alliance. consumer health - Liver Transplant.
  • Genetic Alliance. consumer health - Post-transplant lymphoproliferative disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15707412.001).
  • [ISSN] 1600-6135
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK062329; United States / NCI NIH HHS / CA / P01 CA94237; United States / NCRR NIH HHS / RR / RR00188
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / DNA, Viral; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


39. Bölling T, Ernst I, Könemann S, Willich N: Pediatric radiation oncology in Germany: a study of availability and application. Klin Padiatr; 2008 May-Jun;220(3):178-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric radiation oncology in Germany: a study of availability and application.
  • BACKGROUND: Radiotherapy plays a pivotal role in many multimodal therapy concepts in pediatric oncology.
  • The aim of this study was to evaluate the availability and application of pediatric radiation oncology in Germany.
  • The questions regarded the structure of the departments, the number of irradiated children each year including the distribution of the different diagnoses, the number of curative treatments, inclusion in study trials, and existence of special contact persons for pediatric radiotherapy as well as technical aspects of irradiation of children.
  • Most of these children suffered from brain tumors, Hodgkin's disease and acute lymphatic leukemia (ALL).
  • CONCLUSIONS: Due to quite low patient numbers treated in most radiotherapy facilities, individual experiences in pediatric radiation oncology can be assumed to be quite limited.
  • As radiotherapy is part of multimodal therapy approaches in pediatric oncology and children treated with radiotherapy are at special risk for potential side effects, pediatric radiation oncology remains a sophisticated area.
  • [MeSH-minor] Adolescent. Brachytherapy / utilization. Brain Neoplasms / radiotherapy. Child. Child, Preschool. Germany. Hodgkin Disease / radiotherapy. Humans. Infant. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Radiotherapy, Conformal / utilization. Radiotherapy, Intensity-Modulated / utilization. Surveys and Questionnaires. Utilization Review / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18478491.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


40. Pakakasama S, Sirirat T, Kanchanachumpol S, Udomsubpayakul U, Mahasirimongkol S, Kitpoka P, Thithapandha A, Hongeng S: Genetic polymorphisms and haplotypes of DNA repair genes in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2007 Jan;48(1):16-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms and haplotypes of DNA repair genes in childhood acute lymphoblastic leukemia.
  • This study was performed to evaluate the effect of the polymorphisms of DNA repair genes on risk of childhood acute lymphoblastic leukemia (ALL).
  • CONCLUSION: The XRCC1 194Trp allele and haplotype B showed a protective effect against development of childhood ALL.
  • [MeSH-major] Alleles. DNA Repair. DNA-Binding Proteins / genetics. Genetic Predisposition to Disease. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16435384.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1
  •  go-up   go-down


41. Keates-Baleeiro J, Moore P, Koyama T, Manes B, Calder C, Frangoul H: Incidence and outcome of idiopathic pneumonia syndrome in pediatric stem cell transplant recipients. Bone Marrow Transplant; 2006 Aug;38(4):285-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and outcome of idiopathic pneumonia syndrome in pediatric stem cell transplant recipients.
  • Idiopathic pneumonia syndrome (IPS) is a rare complication following stem cell transplant (SCT) and its incidence among pediatric SCT recipients is not known.
  • There was a significant association between acute or hyperacute graft-versus-host disease (GVHD) and IPS (P=0.035).
  • IPS is a relatively common complication in pediatric SCT recipients and acute GVHD is an important associated factor.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Pneumonia / etiology

  • MedlinePlus Health Information. consumer health - Pneumonia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16819436.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


42. Tan PL, Wagner JE, Auerbach AD, Defor TE, Slungaard A, Macmillan ML: Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation. Pediatr Blood Cancer; 2006 May 1;46(5):630-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation.
  • BACKGROUND: To potentially reduce late effects of malignancy, chronic graft-versus-host disease (GVHD), endocrinopathy, and infertility in patients with Fanconi anemia (FA) undergoing HLA-matched related donor hematopoietic cell transplantation (HCT), we developed a regimen using fludarabine (FLU), cyclophosphamide (CY), and anti-thymocyte globulin (ATG) followed by infusion of T-cell depleted (TCD) bone marrow (BM) or unmanipulated umbilical cord blood (UCB).
  • Stem cell sources were BM and UCB in eight and three patients, respectively.
  • [MeSH-major] Antilymphocyte Serum / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fanconi Anemia / therapy. Graft Survival / drug effects. Hematopoietic Stem Cell Transplantation

  • Genetic Alliance. consumer health - Fanconi Anemia.
  • Genetic Alliance. consumer health - Anemia.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16078221.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R37 HL32987
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


43. Zucchetti M, Meco D, Di Francesco AM, Servidei T, Patriarca V, Cusano G, D'Incalci M, Forestieri D, Pisano C, Riccardi R: Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts. Cancer Chemother Pharmacol; 2010 Sep;66(4):635-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts.
  • PURPOSE: This study compared the antitumor activity and the pharmacological profile of gimatecan given orally and irinotecan (CPT-11) on pediatric tumor xenografts.
  • EXPERIMENTAL DESIGN: Gimatecan was tested in two neuroblastoma cell lines (SK-N-DZ and SK-N-(BE)2c) and on TE-671 rhabdomyosarcoma cells using two different schedules.
  • We characterized its pharmacokinetic profile in nude mice bearing human SK-N-DZ and TE-671 cell lines.
  • CONCLUSION: The antitumor activity and the promising pharmacological profile indicate gimatecan as an excellent candidate for clinical treatment of pediatric tumors.
  • [MeSH-minor] Administration, Oral. Animals. Area Under Curve. Cell Line, Tumor. Cell Proliferation / drug effects. Child. Chromatography, High Pressure Liquid. Half-Life. Humans. Male. Mice. Mice, Nude. Neuroblastoma / drug therapy. Rhabdomyosarcoma / drug therapy. Tetrazolium Salts. Thiazoles. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Oral cancer.
  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20091168.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / ST 1481; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


44. Souzaki R, Tajiri T, Souzaki M, Kinoshita Y, Tanaka S, Kohashi K, Oda Y, Katano M, Taguchi T: Hedgehog signaling pathway in neuroblastoma differentiation. J Pediatr Surg; 2010 Dec;45(12):2299-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study is to show the activation of Hh signaling pathway in neuroblastoma (NB), a pediatric malignancy arising from neural crest cells, and to reveal the meaning of the Hh signaling pathway in NB development.
  • [MeSH-major] Genes, myc. Hedgehog Proteins / physiology. Neoplasm Proteins / physiology. Neuroblastoma / pathology. Receptors, Cell Surface / physiology. Signal Transduction. Transcription Factors / physiology
  • [MeSH-minor] Cell Differentiation. Cell Transformation, Neoplastic. Child, Preschool. Female. Ganglioneuroblastoma / metabolism. Ganglioneuroblastoma / mortality. Ganglioneuroblastoma / pathology. Gene Amplification. Humans. Infant. Japan / epidemiology. Male. Neoplasm Staging. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21129534.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Neoplasm Proteins; 0 / Receptors, Cell Surface; 0 / SHH protein, human; 0 / Transcription Factors; 0 / patched receptors
  •  go-up   go-down


45. Stine KC, Saylors RL, Saccente CS, Becton DL: Treatment of deep vein thrombosis with enoxaparin in pediatric cancer patients receiving chemotherapy. Clin Appl Thromb Hemost; 2007 Apr;13(2):161-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of deep vein thrombosis with enoxaparin in pediatric cancer patients receiving chemotherapy.
  • There are few data regarding the use of enoxaparin in children undergoing myelosuppressive therapy for malignancies even though thrombosis is a known risk in pediatric patients with malignancies.
  • Diagnosis included B-precursor acute lymphoblastic leukemia (ALL) (n=three), T-ALL, Hodgkin's disease, anaplastic large cell lymphoma, and rhabdomyosarcoma (n=one each).

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17456625.001).
  • [ISSN] 1076-0296
  • [Journal-full-title] Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • [ISO-abbreviation] Clin. Appl. Thromb. Hemost.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enoxaparin
  •  go-up   go-down


46. Gruber A, Chalmers AS, Rasmussen RA, Ong H, Popov S, Andersen J, Hu SL, Ruprecht RM: Dendritic cell-based vaccine strategy against human immunodeficiency virus clade C: skewing the immune response toward a helper T cell type 2 profile. Viral Immunol; 2007;20(1):160-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell-based vaccine strategy against human immunodeficiency virus clade C: skewing the immune response toward a helper T cell type 2 profile.
  • We tested the safety and immunogenicity of a multicomponent, cell-based vaccine that consisted of antigen-expressing apoptotic bodies with or without autologous dendritic cells (DCs).
  • The vaccine strategy involved transfection of human 293T cells with codon-optimized DNA vectors expressing env of HIV1084i, a newly transmitted pediatric HIV-1 clade C strain; SHIV89.6P tat; and SIVmac239 gag-protease.
  • Apoptotic bodies were generated by heat shock and ultraviolet irradiation and mixed either with mouse DCs (DC-cell vaccine) or given directly (cell-only vaccine) to BALB/c mice for initial priming; boosts consisted of apoptotic bodies only.
  • Compared with the cell-only vaccine, the DC-cell vaccine induced higher antibody titers against all three antigens, whereas virus-specific cytotoxic T lymphocyte responses were equally strong in both groups.
  • Iso-type analysis of viral antigen-specific antibodies revealed a skewing toward helper T type 2 responses induced by the DC-cell vaccine but not by the cell-only vaccine.


47. Eguchi-Ishimae M, Eguchi M, Kempski H, Greaves M: NOTCH1 mutation can be an early, prenatal genetic event in T-ALL. Blood; 2008 Jan 1;111(1):376-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NOTCH1 mutations are common in T-lineage acute lymphoblastic leukemia (T-ALL).
  • Twin studies and retrospective screening of neonatal blood spots provide evidence that fusion genes and other chromosomal abnormalities associated with pediatric leukemias can originate prenatally.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Leukemia, T-Cell / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor, Notch1 / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17901244.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NOTCH1 protein, human; 0 / Receptor, Notch1
  •  go-up   go-down


48. Barry E, DeAngelo DJ, Neuberg D, Stevenson K, Loh ML, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin M, Cohen HJ, Sallan SE, Silverman LB: Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol; 2007 Mar 1;25(7):813-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
  • PURPOSE: Historically, adolescents with acute lymphoblastic leukemia (ALL) have had inferior outcomes when compared with younger children.
  • Adolescents were more likely to present with T-cell phenotype (P < .001) and less likely to have the TEL-AML1 fusion (P = .05).
  • CONCLUSION: Adolescents were more likely to present at diagnosis with biologically higher risk disease (T-cell phenotype and absence of the TEL-AML1 fusion) and more likely to experience treatment-related complications than younger children.
  • However, the 5-year EFS for older adolescents was 78% +/- 6%, which is superior to published outcomes for similarly aged patients treated with other pediatric and adult ALL regimens.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327603.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 68484
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


49. Jadresin O, Misak Z, Sanja K, Sonicki Z, Zizić V: Compliance with gluten-free diet in children with coeliac disease. J Pediatr Gastroenterol Nutr; 2008 Sep;47(3):344-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Seventy-one patients with CD (mean age = 12 years; mean age after CD diagnosis = 9 years) were examined and their blood sampled for determination of endomysial antibodies (EMA), haemoglobin, and red blood cell count.
  • These patients also had a higher mean body mass (P = 0.05) and significantly higher mean haemoglobin and mean cell haemoglobin levels (P = 0.05 and P < 0.05, respectively).

  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • Hazardous Substances Data Bank. GLUTEN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18728532.001).
  • [ISSN] 1536-4801
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Hemoglobins; 8002-80-0 / Glutens
  •  go-up   go-down


50. Serangeli C, Bicanic O, Scheible MH, Wernet D, Lang P, Rammensee HG, Stevanovic S, Handgretinger R, Feuchtinger T: Ex vivo detection of adenovirus specific CD4+ T-cell responses to HLA-DR-epitopes of the Hexon protein show a contracted specificity of T(HELPER) cells following stem cell transplantation. Virology; 2010 Feb 20;397(2):277-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ex vivo detection of adenovirus specific CD4+ T-cell responses to HLA-DR-epitopes of the Hexon protein show a contracted specificity of T(HELPER) cells following stem cell transplantation.
  • Human adenovirus (HAdV) is a cause of significant morbidity and mortality in immunocompromised patients, especially after stem cell transplantation (SCT).
  • Viral clearance has been attributed to CD4(+) T-cell responses against the Hexon-protein, but the frequency of specific T(HELPER) cells is extremely low or not detectable ex vivo and preference for different CD4(+) T-cell epitopes is variable among individuals.
  • The ex vivo detection of Hexon-specific CD4(+) T-cells, without any long-term culture in vitro, enables the detection and generation of HAdV-specific CD4(+) T cells for adoptive T-cell transfer against HAdV-infection post SCT.
  • [MeSH-major] Adenoviruses, Human / immunology. CD4-Positive T-Lymphocytes / immunology. Capsid Proteins / immunology. Epitopes, T-Lymphocyte / immunology. HLA-DR Antigens / immunology. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • (PMID = 19962170.001).
  • [ISSN] 1096-0341
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Capsid Proteins; 0 / Epitopes, T-Lymphocyte; 0 / HLA-DR Antigens; 0 / hexon capsid protein, Adenovirus; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


51. Baudis M, Prima V, Tung YH, Hunger SP: ABCB1 over-expression and drug-efflux in acute lymphoblastic leukemia cell lines with t(17;19) and E2A-HLF expression. Pediatr Blood Cancer; 2006 Nov;47(6):757-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABCB1 over-expression and drug-efflux in acute lymphoblastic leukemia cell lines with t(17;19) and E2A-HLF expression.
  • BACKGROUND: The t(17;19)(q21;p13), which occurs in a small subset of acute lymphoblastic leukemias (ALLs) and is associated with a dismal prognosis, creates a chimeric E2A-HLF transcription factor with transforming properties.
  • RESULTS: We identified ABCB1 (MDR1, P-glycoprotein) as a gene differentially expressed in ALL cell lines with and without E2A-HLF expression and demonstrated that t(17;19)+ ALL cell lines expressed high levels of ABCB1 protein and had a drug efflux-positive phenotype.
  • [MeSH-major] Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA-Binding Proteins / genetics. Gene Expression Regulation, Neoplastic / genetics. Oncogene Proteins, Fusion / genetics. Organic Anion Transporters / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Transcription Factors / genetics
  • [MeSH-minor] Binding Sites. Biological Transport, Active / drug effects. Biological Transport, Active / genetics. Cell Line, Tumor. Humans. P-Glycoprotein. P-Glycoproteins. Phenotype. Prognosis. RNA, Messenger / drug effects. RNA, Messenger / genetics. Rhodamines / pharmacokinetics. Transcription, Genetic. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16206189.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / DNA-Binding Proteins; 0 / E2a-Hlf fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Organic Anion Transporters; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / RNA, Messenger; 0 / Rhodamines; 0 / Transcription Factors
  •  go-up   go-down


52. Kuroda T, Morikawa N, Matsuoka K, Fujino A, Honna T, Nakagawa A, Kumagai M, Masaki H, Saeki M: Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma. J Pediatr Surg; 2008 Dec;43(12):2182-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Etoposide / administration & dosage. Female. Genes, myc. Hematopoietic Stem Cell Transplantation. Humans. Infant. Kaplan-Meier Estimate. Male. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19040931.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; D58G680W0G / pirarubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


53. Charisius J, Stiefel M, Merkel N, Kornhuber M, Haase R, Kramm CM: Critical illness polyneuropathy: a rare but serious adverse event in pediatric oncology. Pediatr Blood Cancer; 2010 Jan;54(1):161-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical illness polyneuropathy: a rare but serious adverse event in pediatric oncology.
  • Critical illness polyneuropathy (CIP) may aggravate sepsis and multiorgan dysfunction in pediatric oncology patients characterized by quadriparesis and difficult weaning from mechanical ventilation.
  • Here, we report on an adolescent patient with acute lymphoblastic T-cell leukemia who developed critical illness neuropathy after an episode of sepsis with need for mechanical ventilation and intravenous catecholamines.
  • Differential diagnoses like vincristine-induced polyneuropathy, anterior lumbosacral radiculopathy (ALR), Guillain-Barré syndrome, and chronic inflammatory demyelinating polyneuropathy - all occurring in pediatric patients with acute leukemia - are discussed.
  • [MeSH-major] Catecholamines / metabolism. Leukemia, T-Cell / complications. Polyneuropathies / complications. Respiration, Artificial. Sepsis / complications. Vincristine / adverse effects
  • [MeSH-minor] Acute Disease. Adolescent. Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Sepsis.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 19760771.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Catecholamines; 5J49Q6B70F / Vincristine
  •  go-up   go-down


54. Altvater B, Landmeier S, Pscherer S, Temme J, Schweer K, Kailayangiri S, Campana D, Juergens H, Pule M, Rossig C: 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res; 2009 Aug 01;15(15):4857-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells.
  • PURPOSE: Novel natural killer (NK) cell-directed strategies in cancer immunotherapy aim at specifically modulating the balance between NK cell receptor signals toward tumor-specific activation.
  • The signaling lymphocyte activation molecule-related receptor 2B4 (CD244) is an important regulator of NK cell activation.
  • We investigated whether 2B4-enhanced activation signals can redirect the cytolytic function of human NK cells to NK cell-resistant and autologous leukemia and tumor targets.
  • EXPERIMENTAL DESIGN: In vitro-stimulated NK cells from healthy donors and pediatric leukemia patients were gene modified with CD19 or G(D2)-specific chimeric receptors containing either the T-cell receptor zeta or 2B4 endodomain alone or combined.
  • Integration of the 2B4 endodomain into T-cell receptor zeta chimeric receptors significantly enhanced all aspects of the NK cell activation response to antigen-expressing leukemia or neuroblastoma cells, including CD25 up-regulation, secretion of IFN-gamma and tumor necrosis factor-alpha, release of cytolytic granules, and growth inhibition, and overcame NK cell resistance of autologous leukemia cells while maintaining antigen specificity.
  • Antigen-specific 2B4zeta-expressing NK cells may be a powerful new tool for adoptive immunotherapy of leukemia and other malignancies.
  • [MeSH-minor] Antigens, CD19 / immunology. Antigens, CD19 / metabolism. Cell Line, Tumor. Cytotoxicity, Immunologic. Humans. Immunotherapy, Adoptive. Leukemia / immunology. Leukemia / therapy. Lymphocyte Activation / immunology. Lysosomal-Associated Membrane Protein 1 / immunology. Lysosomal-Associated Membrane Protein 1 / metabolism. Neoplasms, Neuroepithelial / immunology. Neoplasms, Neuroepithelial / therapy. Neuroblastoma / immunology. Neuroblastoma / therapy. Protein Engineering. Signal Transduction / immunology. Signaling Lymphocytic Activation Molecule Family

  • Genetic Alliance. consumer health - Neuroblastoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Oct 1;165(7):3549-53 [11034354.001]
  • [Cites] Eur J Immunol. 2000 Mar;30(3):787-93 [10741393.001]
  • [Cites] Nat Biotechnol. 2002 Jan;20(1):70-5 [11753365.001]
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1265-73 [12149207.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16963-8 [12486241.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1637-44 [12393484.001]
  • [Cites] Bone Marrow Transplant. 2003 Jul;32(2):177-86 [12838283.001]
  • [Cites] Leukemia. 2004 Apr;18(4):676-84 [14961035.001]
  • [Cites] J Exp Med. 2004 May 3;199(9):1245-54 [15123744.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7335-40 [15187109.001]
  • [Cites] Br J Haematol. 2004 Aug;126(4):583-92 [15287953.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4 [8421711.001]
  • [Cites] J Immunol. 1993 Jul 1;151(1):60-70 [8326140.001]
  • [Cites] J Exp Med. 1993 Oct 1;178(4):1397-406 [8376943.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6733-7 [7624312.001]
  • [Cites] Hum Gene Ther. 1996 Aug 1;7(12):1405-13 [8844199.001]
  • [Cites] Clin Cancer Res. 1995 Jun;1(6):607-14 [9816022.001]
  • [Cites] Eur J Immunol. 1999 May;29(5):1676-83 [10359122.001]
  • [Cites] Blood Cells Mol Dis. 2004 Nov-Dec;33(3):261-6 [15528141.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9180-4 [15604290.001]
  • [Cites] Blood. 2005 Mar 1;105(5):2066-73 [15536144.001]
  • [Cites] Exp Hematol. 2005 Mar;33(3):344-52 [15730858.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3051-7 [15632206.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4722-9 [15713798.001]
  • [Cites] Blood. 2005 Jul 1;106(1):376-83 [15755898.001]
  • [Cites] Blood. 2006 Jan 1;107(1):159-66 [16150947.001]
  • [Cites] Leukemia. 2006 Apr;20(4):729-32 [16437143.001]
  • [Cites] Leukemia. 2006 Apr;20(4):732-3 [16437151.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3181-8 [15905190.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15 [17062687.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4078-85 [16931625.001]
  • [Cites] Eur J Immunol. 2007 Jan;37(1):193-8 [17171759.001]
  • [Cites] Mol Ther. 2007 Apr;15(4):825-33 [17299405.001]
  • [Cites] Leuk Res. 2007 Oct;31(10):1393-402 [17391757.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5426-35 [17855649.001]
  • [Cites] Cancer Immunol Immunother. 2007 Dec;56(12):1875-83 [17479266.001]
  • [Cites] Cancer Immunol Immunother. 2008 Mar;57(3):411-23 [17717662.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3155-62 [18192509.001]
  • [Cites] J Immunother. 2008 Jun;31(5):475-86 [18463537.001]
  • [Cites] J Immunol. 2008 Jun 15;180(12):8159-67 [18523281.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2261-71 [18509084.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17481-6 [18987320.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):228-36 [11668503.001]
  • [Cites] FEMS Immunol Med Microbiol. 1999 Dec;26(3-4):249-57 [10575136.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2731-6 [10694580.001]
  • [CommentIn] Clin Cancer Res. 2009 Aug 1;15(15):4790-1 [19638468.001]
  • (PMID = 19638467.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501935; United States / NCI NIH HHS / CA / R01 CA113482; United States / NCI NIH HHS / CA / R01 CA113482-04
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD19; 0 / CD244 protein, human; 0 / Lysosomal-Associated Membrane Protein 1; 0 / Receptors, Antigen; 0 / Receptors, Immunologic; 0 / Recombinant Fusion Proteins; 0 / Signaling Lymphocytic Activation Molecule Family
  • [Other-IDs] NLM/ NIHMS154438; NLM/ PMC2771629
  •  go-up   go-down


55. Koehl U, Dirkwinkel E, Koenig M, Erben S, Soerensen J, Bader P, Doerr HW, Preiser W, Weissinger E, Klingebiel T, Martin H, Lehrnbecher T: Reconstitution of cytomegalovirus specific T cells after pediatric allogeneic stem cell transplantation: results from a pilot study using a multi-allele CMV tetramer group. Klin Padiatr; 2008 Nov-Dec;220(6):348-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reconstitution of cytomegalovirus specific T cells after pediatric allogeneic stem cell transplantation: results from a pilot study using a multi-allele CMV tetramer group.
  • BACKGROUND: Recovery of cytomegalovirus (CMV)-specific T cell mediated immunity after allogeneic hematopoietic stem cell transplantation (SCT) is critical for protection against CMV disease.
  • [MeSH-major] Alleles. Antibody Specificity / immunology. Antigens, Viral / immunology. CD8-Positive T-Lymphocytes / immunology. Cytomegalovirus / immunology. Cytomegalovirus Infections / immunology. Hematopoietic Stem Cell Transplantation / methods. Neoplasms / therapy. Opportunistic Infections / immunology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949669.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Immunosuppressive Agents
  •  go-up   go-down


56. Laosombat V, Viprakasit V, Dissaneevate S, Leetanaporn R, Chotsampancharoen T, Wongchanchailert M, Kodchawan S, Thongnoppakun W, Duangchu S: Natural history of Southeast Asian Ovalocytosis during the first 3 years of life. Blood Cells Mol Dis; 2010 Jun 15;45(1):29-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Southeast Asian Ovalocytosis (SAO), the most common red cell membrane disorder found in the Far-East and Pacific rim, appears to be innocuous in man since it has been identified mostly in non-anemic healthy individuals.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright 2010. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20421175.001).
  • [ISSN] 1096-0961
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anion Exchange Protein 1, Erythrocyte; EC 2.4.1.- / UGT1A1 enzyme; EC 2.4.1.17 / Glucuronosyltransferase
  •  go-up   go-down


57. Feichtl RE, Rosenfeld B, Tallamy B, Cairo MS, Sands SA: Concordance of quality of life assessments following pediatric hematopoietic stem cell transplantation. Psychooncology; 2010 Jul;19(7):710-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concordance of quality of life assessments following pediatric hematopoietic stem cell transplantation.
  • PURPOSE: To examine the concordance between pediatric patient's self-report and parent-report regarding a patient's quality of life (QoL) prior to and following hematopoietic stem cell transplantation (HSCT) and to identify potential medical and demographic covariates of concordance.
  • PATIENTS AND METHODS: Utilizing the PedsQL 4.0, the longitudinal QoL data were obtained from 68 pediatric HSCT patient-parent dyads prior to and up to two years post-transplantation.
  • RESULTS: Reliability based upon Intraclass Correlation Coefficients (ICC) indicates a parabolic pattern of concordance being significantly poorer in the acute phase of treatment 3 months post-HSCT, followed by a return to pre-transplant levels at subsequent assessments and a substantial rise at one- and two-year follow-up assessments (Baseline ICC = 0.42; 3 months = 0.11; 6 months = 0.54).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / psychology. Parents / psychology. Sick Role

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19823975.001).
  • [ISSN] 1099-1611
  • [Journal-full-title] Psycho-oncology
  • [ISO-abbreviation] Psychooncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


58. Mann G, Cazzaniga G, van der Velden VH, Flohr T, Csinady E, Paganin M, Schrauder A, Dohnal AM, Schrappe M, Biondi A, Gadner H, van Dongen JJ, Panzer-Grümayer ER: Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: The 'big sister' of the infant disease? Leukemia; 2007 Apr;21(4):642-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia with t(4;11) in children 1 year and older: The 'big sister' of the infant disease?
  • The t(4;11)-positive acute lymphoblastic leukemia (ALL) is a rare disease in children above the age of 1 year.
  • We studied the clinical and biological characteristics in 32 consecutively diagnosed childhood cases (median age 10.0 years, range 1.0-17.1 years).
  • /2.3 gene segment, an unusual combination among t(4;11)-negative B-cell precursor ALL.
  • Our data are in line with transformation of a precursor cell at an early stage of B-cell development but retaining the potential to differentiate to the pre-B cell stage in vivo.
  • Although a distinct difference between infant and older childhood cases with t(4;11) became evident, no age-related biological features were found within the childhood age group.
  • In contrast to infants with t(4;11)-positive ALL, childhood cases had a relatively low cumulative incidence of relapse of 25% at 3.5 years with BFM-based high-risk protocols.
  • [MeSH-major] Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 4. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic
  • [MeSH-minor] Genes, Immunoglobulin. Humans. Immunoglobulin Heavy Chains / genetics. Immunophenotyping. Infant. Neoplasm Staging. Receptors, Antigen, T-Cell / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17287854.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


59. Attarbaschi A, Pisecker M, Inthal A, Mann G, Janousek D, Dworzak M, Pötschger U, Ullmann R, Schrappe M, Gadner H, Haas OA, Panzer-Grümayer R, Strehl S, Austrian Berlin-Frankfurt-Münster (BFM) Study Group: Prognostic relevance of TLX3 (HOX11L2) expression in childhood T-cell acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing early and late re-intensification elements. Br J Haematol; 2010 Jan;148(2):293-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic relevance of TLX3 (HOX11L2) expression in childhood T-cell acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing early and late re-intensification elements.
  • TLX3 expression (TLX3+) in childhood T-cell acute lymphoblastic leukaemia (T-ALL) seems to be associated with a poor prognosis when treated with regimens that lack early and/or late re-intensification therapy elements.
  • Thirty-one/131 childhood T-ALL cases (24%) enrolled into four population-based Austrian ALL-BFM therapy studies were TLX3+.
  • After a median observation time of 4.9 years (range 0.4-16.1 years) 28/31 TLX3+ cases remained in first complete remission after chemotherapy with one after additional stem cell transplantation.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Homeodomain Proteins / metabolism. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19821827.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Homeodomain Proteins; 0 / NUP214-ABL1 fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / TLX3 protein, human; 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


60. Rivero-Vergne A, Berrios R, Romero I: Cultural aspects of the Puerto Rican cancer experience: the mother as the main protagonist. Qual Health Res; 2008 Jun;18(6):811-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pediatric cancer survivors are a growing group whose needs extend to multiple contexts and systems.
  • Most studies dealing with the emotional sequelae of childhood cancer have neglected patients' and parents' perspectives.
  • Using a phenomenological approach, in-depth interviews were conducted with acute lymphoblastic leukemia (ALL) patients, their mothers, and their oncology treatment team (18) at a children's hospital in Puerto Rico.
  • [MeSH-major] Health Knowledge, Attitudes, Practice. Mothers / psychology. Parent-Child Relations / ethnology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / ethnology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18503022.001).
  • [ISSN] 1049-7323
  • [Journal-full-title] Qualitative health research
  • [ISO-abbreviation] Qual Health Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


61. Rakheja D, Kapur P, Tomlinson GE, Margraf LR: Pediatric renal cell carcinomas with Xp11.2 rearrangements are immunoreactive for hMLH1 and hMSH2 proteins. Pediatr Dev Pathol; 2005 Nov-Dec;8(6):615-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric renal cell carcinomas with Xp11.2 rearrangements are immunoreactive for hMLH1 and hMSH2 proteins.
  • Alveolar soft part sarcoma and pediatric renal cell carcinoma share a similar chromosomal abnormality, t(X;17)(p11.2;q25).
  • We performed immunohistochemistry for hMLH1 and hMSH2 in 4 cases of pediatric renal cell carcinomas with Xp11.2 rearrangements.
  • Our study demonstrates that inactivation of the DNA mismatch repair genes hMLH1 and hMSH2 does not appear to play a role in the tumorigenesis of pediatric renal cell carcinomas with Xp11.2 rearrangements.
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / metabolism. Carrier Proteins / biosynthesis. Kidney Neoplasms / genetics. Kidney Neoplasms / metabolism. Neoplasm Proteins / biosynthesis. Nuclear Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16328670.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / MLH1 protein, human; 0 / MLH2 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins
  •  go-up   go-down


62. Gualco G, Weiss LM, Barber GN, Bacchi CE: T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. Hum Pathol; 2010 Sep;41(9):1238-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell leukemia 1 expression in nodal Epstein-Barr virus-negative diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.
  • The physiologic expression of the product of the proto-oncogene TCL1 (T-cell leukemia 1) is primarily restricted to early embryonic cells.
  • It has been shown that TCL1 is a powerful B-cell oncogene, which has been implicated in the pathogenesis of various types of mature B-cell lymphomas.
  • There is no comparative information in the literature addressing the expression of TCL1 in pediatric and adult nodal diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma.
  • We studied 55 cases of adult and pediatric diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma to analyze the phenotypic profile of these lymphomas, including TCL1 expression, and its relationship with clinical outcome in different age groups.
  • TCL1 was observed in 11 cases, 5 pediatric and 6 adult cases, all but one diffuse large B-cell lymphoma.
  • Pediatric cases showed a significant association between TCL1 expression, high proliferative index, and presence of c-MYC translocation.
  • TCL1 positivity was predominantly found in germinal center phenotype diffuse large B-cell lymphoma.
  • Overall survival was worse in adult TCL1-positive cases than pediatric ones.
  • Primary mediastinal large B-cell lymphomas infrequently expressed TCL1 in both age groups.
  • [MeSH-major] Epstein-Barr Virus Infections / metabolism. Herpesvirus 4, Human / isolation & purification. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Mediastinal Neoplasms / metabolism. Proto-Oncogene Proteins / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20382409.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / TCL1A protein, human
  •  go-up   go-down


63. Sidhom I, Shaaban K, Soliman S, Ezzat S, El-Anwar W, Hamdy N, Yassin D, Salem S, Hassanein H, Mansour MT: Clinical significance of immunophenotypic markers in pediatric T-cell acute lymphoblastic leukemia. J Egypt Natl Canc Inst; 2008 Jun;20(2):111-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of immunophenotypic markers in pediatric T-cell acute lymphoblastic leukemia.
  • BACKGROUND: Cell-marker profiling has led to conflicting conclusions about its prognostic significance in T-ALL.
  • AIM: To investigate the prevalence of the expression of CD34, CD10 and myeloid associated antigens (CD13/ CD33) in childhood T-ALL and to relate their presence to initial clinical and biologic features and early response to therapy.
  • No significant association was encountered between CD34, CD10 or myeloid antigen positivity and the presenting clinical features as age, sex, TLC and CNS leukemia.
  • CD34 and CD13/CD33 expression was significantly associated with T-cell maturation stages (p<0.05).
  • CD34(+), CD13/CD33(+) and early T-cell stage had high MRD levels on day 15 that was statistically highly significant (p<0.01), but CD10(+) had statistically significant lower MRD level on day 15 (p=0.049).
  • CONCLUSIONS: CD34, CD10, CD13/CD33 expression, as well as T-cell maturation stages, may have prognostic significance in pediatric T-ALL as they have a significant impact on early clearance of leukemic cells detected by MRD day 15.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Neoplasm, Residual / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Antigens, CD / metabolism. Antigens, CD13 / metabolism. Antigens, CD34 / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Cell Differentiation. Child. Child, Preschool. Egypt. Female. Flow Cytometry. Humans. Immunophenotyping. Infant. Male. Neprilysin / metabolism. Prognosis. Remission Induction. Sialic Acid Binding Ig-like Lectin 3. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20029466.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 3.4.11.2 / Antigens, CD13; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


64. Deneau M, Wallentine J, Guthery S, O'Gorman M, Bohnsack J, Fluchel M, Bezzant J, Pohl JF: Natural killer cell lymphoma in a pediatric patient with inflammatory bowel disease. Pediatrics; 2010 Oct;126(4):e977-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural killer cell lymphoma in a pediatric patient with inflammatory bowel disease.
  • Skin biopsy revealed an atypical lymphoid infiltrate consistent with an Epstein-Barr virus (EBV)-positive natural killer (NK)/T-cell lymphoma with associated hemophagocytic lymphohistiocytosis.
  • Bone marrow biopsy revealed a similar EBV-positive lymphoid infiltrate consistent with an NK/T-cell lymphoma.
  • Flow-cytometric analysis revealed an atypical, clonal NK-cell population, and biopsy specimens from several tissue sites tested positive for CD3, CD56, and CD30.
  • [MeSH-major] Inflammatory Bowel Diseases / complications. Inflammatory Bowel Diseases / drug therapy. Lymphoma, Extranodal NK-T-Cell / complications

  • Hazardous Substances Data Bank. Infliximab .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20837584.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000077
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Gastrointestinal Agents; 0 / Tumor Necrosis Factor-alpha; B72HH48FLU / Infliximab
  •  go-up   go-down


65. Alakulppi N, Seikku P, Jaatinen T, Holmberg C, Laine J: Feasibility of diagnosing subclinical renal allograft rejection in children by whole blood gene expression analysis. Transplantation; 2008 Nov 15;86(9):1222-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Whole blood samples taken at the time of 3- or 6-month protocol biopsy in 31 pediatric renal transplant recipients, 13 of whom had biopsy-proven subclinical rejection (SCR), were studied.
  • In all patients, the gene expression of candidate genes CD154 and inducible T-cell co-stimulator (ICOS) was measured.
  • [MeSH-minor] Adolescent. Antigens, Differentiation, T-Lymphocyte / genetics. Antigens, Differentiation, T-Lymphocyte / metabolism. Biomarkers / blood. Biopsy. CD40 Ligand / genetics. CD40 Ligand / metabolism. Child. Child, Preschool. Feasibility Studies. Female. Humans. Inducible T-Cell Co-Stimulator Protein. Infant. Kidney / metabolism. Kidney / pathology. Male. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19005403.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Biomarkers; 0 / ICOS protein, human; 0 / Inducible T-Cell Co-Stimulator Protein; 147205-72-9 / CD40 Ligand
  •  go-up   go-down


66. Rudy BJ, Sleasman J, Kapogiannis B, Wilson CM, Bethel J, Serchuck L, Ahmad S, Cunningham CK, Adolescent Trials Network for HIV/AIDS Interventions: Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression. AIDS Res Hum Retroviruses; 2009 Jun;25(6):555-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subjects were recruited by the Adolescent Trials Network for HIV/AIDS Interventions and the Pediatric AIDS Clinical Trials Group.
  • Subjects were infected either through perinatal/early childhood transmission or later via risk behaviors.
  • All subjects were required to have at least 6 months of documented viral suppression below 400 copies/ml plus a preentry value below 200 copies/ml and an entry CD4+ T cell count above 350 cells/mm3.
  • There was no impact of SCT on the CD4+ T cell counts in those who remained on study or those who came off SCT for any reason.

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Adherence to HIV Antiretroviral Therapy .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):853-60 [9516219.001]
  • [Cites] AIDS Res Hum Retroviruses. 2007 Oct;23(10):1208-14 [17961106.001]
  • [Cites] Clin Infect Dis. 2005 Mar 1;40(5):728-34 [15714420.001]
  • [Cites] JAMA. 2005 Feb 16;293(7):817-29 [15713771.001]
  • [Cites] PLoS Med. 2004 Dec;1(3):e64 [15630469.001]
  • [Cites] J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):523-9 [16044002.001]
  • [Cites] AIDS Patient Care STDS. 2005 Jul;19(7):425-8 [16053399.001]
  • [Cites] Arch Pediatr Adolesc Med. 2005 Aug;159(8):764-70 [16061785.001]
  • [Cites] Clin Infect Dis. 2005 Sep 15;41(6):883-90 [16107990.001]
  • [Cites] Cochrane Database Syst Rev. 2005;(4):CD005482 [16235406.001]
  • [Cites] AIDS Res Hum Retroviruses. 2006 Mar;22(3):213-21 [16545007.001]
  • [Cites] Lancet. 2006 Jun 17;367(9527):1981-9 [16782488.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(3):CD006148 [16856117.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15161-6 [11734634.001]
  • [Cites] N Engl J Med. 2003 Aug 28;349(9):837-46 [12944569.001]
  • [Cites] J Infect Dis. 2004 Jun 1;189(11):1974-82 [15143462.001]
  • [Cites] J Infect Dis. 2004 Jul 15;190(2):271-9 [15216461.001]
  • [Cites] J Exp Med. 1995 Dec 1;182(6):1727-37 [7500017.001]
  • [Cites] World Health Organ Tech Rep Ser. 2006;938:1-13; discussion 317-41 [16921915.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Oct 1;43(2):169-78 [16951642.001]
  • [Cites] N Engl J Med. 2006 Nov 30;355(22):2283-96 [17135583.001]
  • [Cites] Curr HIV Res. 2007 Mar;5(2):235-50 [17346137.001]
  • [Cites] HIV Clin Trials. 2007 Jan-Feb;8(1):19-23 [17434845.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):418-25 [17468667.001]
  • [Cites] Clin Infect Dis. 2005 Feb 15;40(4):594-600 [15712083.001]
  • (PMID = 19534628.001).
  • [ISSN] 1931-8405
  • [Journal-full-title] AIDS research and human retroviruses
  • [ISO-abbreviation] AIDS Res. Hum. Retroviruses
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / U01 HD 040533; United States / NICHD NIH HHS / HD / U01 HD040533; United States / NICHD NIH HHS / HD / U01 HD 040474; United States / NICHD NIH HHS / HD / U01 HD040474; United States / PHS HHS / / U01-A141089; United States / NCRR NIH HHS / RR / 5-M01-RR-020359-04; United States / NIAID NIH HHS / AI / R01 AI047723; United States / NCRR NIH HHS / RR / UL1-RR-024134
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  • [Other-IDs] NLM/ PMC2853866
  • [Investigator] D'Angelo; Trexler; Crane; Rudy; Tanney; DiBenedetto; Martinez; Bojan; Jackson; Henry-Reid; Febo; Ayala; Flores; Santos; Futterman; Enriquez-Bruce; Campos; Myerson; Levin-Carmine; Geiger; Lee; Abdalian; Kozina; Baker; Friedman; Maturo; Major-Wilson; Puga; Leonard; Eysallanne; Inman; Flynn; Patel; Utech; Donohoe; Yogev; Heald; Kershaw; Weiner; Holz; Contello; Famiglietti
  •  go-up   go-down


67. Urschel S, Campbell PM, Meyer SR, Larsen IM, Nuebel J, Birnbaum J, Netz H, Tinckam K, Kauke T, Derkatz K, Coe JY, Platt JL, West LJ: Absence of donor-specific anti-HLA antibodies after ABO-incompatible heart transplantation in infancy: altered immunity or age? Am J Transplant; 2010 Jan;10(1):149-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific B-cell tolerance toward donor blood group antigens develops in infants after ABO-incompatible heart transplantation, whereas their immune response toward protein antigens such as HLA has not been investigated.
  • We assessed de novo HLA-antibodies in 122 patients after pediatric thoracic transplantation (28 ABO-incompatible) and 36 controls.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Heart Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 2000 Feb;119(2):324-30 [10649208.001]
  • [Cites] J Heart Lung Transplant. 2008 Sep;27(9):970-7 [18765188.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):793-800 [11248154.001]
  • [Cites] Clin Dev Immunol. 2003 Jun-Dec;10(2-4):213-26 [14768954.001]
  • [Cites] Hum Immunol. 2004 Apr;65(4):282-90 [15120183.001]
  • [Cites] JAMA. 1994 Oct 12;272(14):1116-21 [7933324.001]
  • [Cites] J Immunol. 1995 Feb 15;154(4):1560-8 [7530739.001]
  • [Cites] Immunol Rev. 1997 Feb;155:105-17 [9059886.001]
  • [Cites] Transplantation. 1997 Oct 27;64(8):1175-80 [9355836.001]
  • [Cites] Vaccine. 1998 Aug-Sep;16(14-15):1396-400 [9711778.001]
  • [Cites] Nat Med. 2004 Nov;10(11):1227-33 [15502841.001]
  • [Cites] Nature. 1953 Oct 3;172(4379):603-6 [13099277.001]
  • [Cites] Eur J Cardiothorac Surg. 2005 Apr;27(4):554-60 [15784350.001]
  • [Cites] Curr Opin Immunol. 2005 Jun;17(3):237-43 [15886112.001]
  • [Cites] Hum Immunol. 2005 May;66(5):513-8 [15935888.001]
  • [Cites] Infect Dis Clin North Am. 2005 Sep;19(3):629-45 [16102653.001]
  • [Cites] Transplantation. 2005 Oct 27;80(8):1019-25 [16278580.001]
  • [Cites] J Immunol. 2005 Dec 15;175(12):8011-23 [16339538.001]
  • [Cites] Transplantation. 2006 Feb 15;81(3):301-7 [16477211.001]
  • [Cites] J Heart Lung Transplant. 2007 Jun;26(6):565-71 [17543778.001]
  • [Cites] Transplantation. 2007 Sep 27;84(6):738-45 [17893607.001]
  • [Cites] J Heart Lung Transplant. 2008 Oct;27(10):1090-5 [18926399.001]
  • [Cites] Transplantation. 2008 Oct 27;86(8):1111-5 [18946350.001]
  • [Cites] J Heart Lung Transplant. 2009 Feb;28(2):123-9 [19201336.001]
  • [Cites] Nephrology (Carlton). 2009 Apr;14(2):247-54 [19207861.001]
  • [Cites] J Thorac Cardiovasc Surg. 2010 Sep;140(3):694-9, 699.e1-2 [20537356.001]
  • [Cites] Ann Thorac Surg. 2007 Nov;84(5):1556-62; discussion 1562-3 [17954062.001]
  • [Cites] Am J Transplant. 2008 Jan;8(1):208-15 [18021280.001]
  • [Cites] Clin Transpl. 2006;:455-62 [18365403.001]
  • [Cites] Transplantation. 2008 Jun 27;85(12):1705-14 [18580460.001]
  • [Cites] Transplantation. 2000 Apr 15;69(7):1370-4 [10798756.001]
  • (PMID = 19951279.001).
  • [ISSN] 1600-6143
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL079067; United States / NHLBI NIH HHS / HL / HL52297; United States / NHLBI NIH HHS / HL / P01 HL079067-049001; United States / NHLBI NIH HHS / HL / HL079067-049001; Canada / Canadian Institutes of Health Research / / ; United States / NHLBI NIH HHS / HL / R01 HL052297; United States / NHLBI NIH HHS / HL / R37 HL052297; United States / NHLBI NIH HHS / HL / HL79067
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABO Blood-Group System; 0 / HLA Antigens; 0 / HLA-D Antigens; 0 / Histocompatibility Antigens Class I; 0 / Isoantibodies
  • [Other-IDs] NLM/ NIHMS152711; NLM/ PMC2806931
  •  go-up   go-down


68. Kalinova M, Krskova L, Brizova H, Kabickova E, Kepak T, Kodet R: Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma--residual disease monitoring and a correlation with the disease status. Leuk Res; 2008 Jan;32(1):25-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative PCR detection of NPM/ALK fusion gene and CD30 gene expression in patients with anaplastic large cell lymphoma--residual disease monitoring and a correlation with the disease status.
  • Anaplastic large cell lymphoma (ALCL) represents a heterogeneous group of malignant lymphoproliferative diseases with a consistent expression of the cytokine receptor CD30.
  • ALCL is frequently associated with a NPM/ALK fusion gene which is found in up to 75% of pediatric ALCLs.
  • [MeSH-major] Antigens, CD30 / genetics. Lymphoma, Large-Cell, Anaplastic / genetics. Neoplasm, Residual / genetics. Protein-Tyrosine Kinases / genetics

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320171.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


69. Iruloh CG, D'Souza SW, Fergusson WD, Baker PN, Sibley CP, Glazier JD: Amino acid transport systems beta and A in fetal T lymphocytes in intrauterine growth restriction and with tumor necrosis factor-alpha treatment. Pediatr Res; 2009 Jan;65(1):51-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After 24 or 48 h TNF-alpha treatment, fetal T lymphocytes from normal pregnancies showed no significant change in system A or system beta activity, although cell viability was compromised.
  • This study represents the first characterization of amino acid transport in a fetal cell outside the placenta in IUGR.
  • [MeSH-minor] Birth Weight. Cell Survival. Cells, Cultured. Female. Fetal Blood / immunology. Fetal Blood / metabolism. Gestational Age. Humans. Infant, Newborn. Male. Pregnancy. RNA, Messenger / metabolism. Recombinant Proteins / metabolism. Time Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Res. 1993 Nov;34(5):661-5 [8284106.001]
  • [Cites] Am J Physiol. 1993 Jul;265(1 Pt 1):E31-5 [8338151.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Oct;104(10):1116-22 [9332987.001]
  • [Cites] Pediatr Res. 1997 Oct;42(4):514-9 [9380446.001]
  • [Cites] Pediatr Res. 1998 Aug;44(2):233-8 [9702920.001]
  • [Cites] Pediatr Res. 1998 Oct;44(4):532-7 [9773842.001]
  • [Cites] Pediatr Res. 2005 Nov;58(5):827-32 [16183820.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Jan;290(1):C305-12 [16148032.001]
  • [Cites] Placenta. 2006 Apr-May;27(4-5):510-6 [16023720.001]
  • [Cites] J Physiol. 2006 Nov 1;576(Pt 3):935-46 [16916910.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Jan;292(1):C332-41 [16956961.001]
  • [Cites] Clin Sci (Lond). 2007 Jul;113(1):1-13 [17536998.001]
  • [Cites] Biotechnol Bioeng. 2007 Aug 1;97(5):1216-29 [17171720.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jul 14;273(3):1175-9 [10891391.001]
  • [Cites] Biochim Biophys Acta. 2000 Jul 31;1467(1):1-6 [10930503.001]
  • [Cites] Pediatr Res. 2001 Feb;49(2):141-7 [11158505.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2001 Sep;4(5):425-31 [11568505.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Jan;282(1):C153-60 [11742808.001]
  • [Cites] FEBS Lett. 2002 Apr 24;517(1-3):92-6 [12062416.001]
  • [Cites] Placenta. 2002 May;23(5):392-9 [12061855.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):945-8 [12087403.001]
  • [Cites] Pediatr Int. 2002 Dec;44(6):590-5 [12421253.001]
  • [Cites] J Neurochem. 2002 Dec;83(5):1188-95 [12437590.001]
  • [Cites] Acta Obstet Gynecol Scand. 2003 Dec;82(12):1099-102 [14616253.001]
  • [Cites] Pflugers Arch. 2004 Feb;447(5):784-95 [12845534.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2004 Oct;287(4):R886-93 [15166008.001]
  • [Cites] Br Med J (Clin Res Ed). 1985 Sep 28;291(6499):845-8 [3931739.001]
  • [Cites] Acta Paediatr Scand Suppl. 1985;319:143-9 [3914183.001]
  • [Cites] Am J Obstet Gynecol. 1989 Nov;161(5):1219-27 [2589443.001]
  • [Cites] Br J Obstet Gynaecol. 1993 Apr;100(4):342-7 [8494835.001]
  • [Cites] Am J Obstet Gynecol. 1996 May;174(5):1575-83 [9065132.001]
  • (PMID = 18703994.001).
  • [ISSN] 1530-0447
  • [Journal-full-title] Pediatric research
  • [ISO-abbreviation] Pediatr. Res.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 071224; United Kingdom / Wellcome Trust / / (071224/Z/03/Z
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acid Transport System A; 0 / Membrane Glycoproteins; 0 / Membrane Transport Proteins; 0 / RNA, Messenger; 0 / Recombinant Proteins; 0 / SLC38A1 protein, human; 0 / SLC38A2 protein, human; 0 / SLC38A4 protein, human; 0 / Tumor Necrosis Factor-alpha; 148686-53-7 / taurine transporter
  • [Other-IDs] NLM/ PMC3087423; NLM/ UKMS34686
  •  go-up   go-down


70. Luczyński W, Stasiak-Barmuta A, Iłendo E, Kovalchuk O, Krawczuk-Rybak M, Malinowska I, Mitura-Lesiuk M, Chyczewski L, Matysiak M, Kowalczyk J, Jaworowski R: Low expression of costimulatory molecules and mRNA for cytokines are important mechanisms of immunosuppression in acute lymphoblastic leukemia in children? Neoplasma; 2006;53(4):301-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low expression of costimulatory molecules and mRNA for cytokines are important mechanisms of immunosuppression in acute lymphoblastic leukemia in children?
  • Mechanisms leading blasts of acute lymphoblastic leukemia to escape from immune surveillance are still unknown.
  • Children with B-cell precursor ALL (n=20) were prospectively enrolled into the study.
  • [MeSH-major] Antigens, CD / metabolism. Cytokines / metabolism. Immune Tolerance. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16830056.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Cytokines; 0 / RNA, Messenger
  •  go-up   go-down


71. Hřebačková J, Poljaková J, Eckschlager T, Hraběta J, Procházka P, Smutný S, Stiborová M: Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells. Interdiscip Toxicol; 2009 Sep;2(3):205-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, the toxicity of both drugs to human neuroblastoma cell lines was investigated using MTT test, and IC50 values for both compounds were determined.
  • A malignant subset of neuroblastoma cells, so-called N-type cells (UKF-NB-3 cells) and the more benign S-type neuroblastoma cells (UKF-NB-4 and SK-N-AS cell lines) were studied from both two points of view.
  • Of the neuroblastoma tested here, the N-type UKF-NB-3 cell line was the most sensitive to both drugs.
  • Protein expression of all these CYP enzymes in the S-type SK-N-AS cell line was not influenced by either of studied drugs.
  • On the contrary, in another S-type cell line, UKF-NB-4, VPA and TSA induced expression of CYP1A1, depressed levels of CYP1B1 and had no effect on expression levels of CYP3A4 enzyme.
  • In the N-type UKF-NB-3 cell line, the expression of CYP1A1 was strongly induced, while that of CYP1B1 depressed by VPA and TSA.
  • VPA also induced the expression of CYP3A4 in this neuroblastoma cell line.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Pharm Des. 2007;13(33):3378-93 [18045192.001]
  • [Cites] Cancer Treat Rev. 2008 May;34(3):206-22 [18226465.001]
  • [Cites] Cancer Lett. 2009 Aug 8;280(2):192-200 [19345475.001]
  • [Cites] Biochem Pharmacol. 2009 May 1;77(9):1466-79 [19426684.001]
  • [Cites] Epilepsia. 1991 Jan-Feb;32(1):146-50 [1985825.001]
  • [Cites] Gene Expr. 1996;5(4-5):245-53 [8723390.001]
  • [Cites] Anticancer Drugs. 1996 Sep;7(7):766-73 [8949988.001]
  • [Cites] Eur J Biochem. 1995 Jul 15;231(2):337-43 [7635145.001]
  • [Cites] Oncol Res. 2004;14(7-8):345-54 [15301425.001]
  • [Cites] Toxicol Sci. 2006 Dec;94(2):261-71 [16945988.001]
  • [Cites] Drug Metab Dispos. 2007 Jul;35(7):1032-41 [17392393.001]
  • [Cites] BMC Dev Biol. 2007;7:24 [17407549.001]
  • [Cites] Br J Pharmacol. 2008 Feb;153(4):657-68 [18059320.001]
  • [Cites] Biochemistry (Mosc). 2008 Sep;73(9):965-9 [18976212.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2264-79 [10561284.001]
  • [Cites] Cell Adhes Commun. 2000 May;7(5):423-40 [10830620.001]
  • [Cites] Epilepsia. 2001 Jul;42(7):930-4 [11488894.001]
  • [Cites] Br J Clin Pharmacol. 2001 Nov;52(5):547-53 [11736863.001]
  • [Cites] Oncogene. 2002 Sep 5;21(39):6132-7 [12203125.001]
  • [Cites] Med Res Rev. 2002 Sep;22(5):492-511 [12210556.001]
  • [Cites] Nat Rev Cancer. 2003 Mar;3(3):203-16 [12612655.001]
  • [Cites] Curr Opin Pharmacol. 2003 Aug;3(4):344-51 [12901942.001]
  • [Cites] Endocrinology. 2004 Feb;145(2):799-808 [14576182.001]
  • [Cites] Pharm Weekbl Sci. 1992 Jun 19;14(3A):127-31 [1502013.001]
  • [Cites] Arch Biochem Biophys. 2004 Jun 1;426(1):63-72 [15130783.001]
  • [Cites] Acta Paediatr Suppl. 2004 May;93(445):78-84; discussion 84-5 [15176727.001]
  • [Cites] Adv Cancer Res. 2004;91:137-68 [15327890.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1795-9 [15547719.001]
  • [Cites] Bioorg Med Chem Lett. 2005 Mar 1;15(5):1283-7 [15713371.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3815-22 [15867379.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):769-84 [16955068.001]
  • [Cites] Curr Drug Metab. 2007 May;8(4):383-93 [17504226.001]
  • (PMID = 21217856.001).
  • [ISSN] 1337-9569
  • [Journal-full-title] Interdisciplinary toxicology
  • [ISO-abbreviation] Interdiscip Toxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  • [Other-IDs] NLM/ PMC2984103
  • [Keywords] NOTNLM ; cytotoxicity / histone deacetylase inhibitors / neuroblastoma / trichostatin A / valproate
  •  go-up   go-down


72. Le Henaff G, Corradini N, Gras C, Méchinaud F: [Adenovirus infections in children: experience in the field of the allogeneic stem cell transplantation]. Arch Pediatr; 2007 Jul;14(7):900-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenovirus infections in children: experience in the field of the allogeneic stem cell transplantation].
  • Adenovirus (Adv) infections are frequent in pediatric patients, sometimes serious, above all in immunocompromised children.
  • We report the cases of 2 children who presented an Adv infection after allogeneic stem cell transplantation (SCT).
  • DISCUSSION: T-cell depletion (mainly carried out in vivo at present) is the major risk factor of Adv infection after allogeneic SCT.
  • [MeSH-major] Adenoviridae Infections / etiology. Stem Cell Transplantation / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17459677.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


73. Hijiya N, Ness KK, Ribeiro RC, Hudson MM: Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues. Cancer; 2009 Jan 1;115(1):23-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues.
  • Secondary acute leukemia is a devastating complication in children and adolescents who have been treated for cancer.
  • Secondary acute lymphoblastic leukemia (s-ALL) was rarely reported previously but can be distinguished today from recurrent primary ALL by comparison of immunoglobulin and T-cell receptor rearrangement.
  • Secondary acute myeloid leukemia (s-AML) is much more common, and some cases actually may be second primary cancers.
  • The prevalence of alkylator-associated s-AML has diminished among pediatric oncology patients with the reduction of cumulative alkylator dose and limited use of the more leukemogenic alkylators.
  • More studies are needed to confirm this finding in the pediatric patient population.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PODOFILOX .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • [Cites] Lancet. 1996 Feb 3;347(8997):295-7 [8569364.001]
  • [Cites] N Engl J Med. 1996 Mar 21;334(12):745-51 [8592547.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 18;88(24):1840-7 [8961974.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):1049-54 [9041170.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2247-53 [9196137.001]
  • [Cites] Leukemia. 1998 Mar;12(3):346-52 [9529129.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3617-23 [10339466.001]
  • [Cites] Blood. 1999 Jul 15;94(2):803-7 [10397748.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3221-5 [10506622.001]
  • [Cites] Bone Marrow Transplant. 1999 Oct;24(7):735-9 [10516676.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4926-33 [15611507.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):926-7 [15681547.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Leukemia. 2006 Feb;20(2):239-46 [16341039.001]
  • [Cites] Oncogene. 2006 Sep 25;25(43):5875-84 [16998502.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Nov;15(11):2020-6 [17057028.001]
  • [Cites] Blood. 2007 Jan 1;109(1):46-51 [16985182.001]
  • [Cites] Bone Marrow Transplant. 2007 Jan;39(2):59-70 [17143301.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):292-300 [17159192.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 7;99(3):196-205 [17284714.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):493-500 [17290056.001]
  • [Cites] Best Pract Res Clin Haematol. 2007 Mar;20(1):29-37 [17336252.001]
  • [Cites] JAMA. 2007 Mar 21;297(11):1207-15 [17374815.001]
  • [Cites] Leukemia. 2007 Jul;21(7):1431-5 [17460701.001]
  • [Cites] Ophthalmology. 2007 Jul;114(7):1378-83 [17613328.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1379-87 [17488876.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3871-6 [17664457.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Sep;29(9):646-8 [17805043.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):233-55 [9748598.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13176-81 [9789061.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3880-9 [9850034.001]
  • [Cites] Bone Marrow Transplant. 1999 Jan;23(1):21-5 [10037046.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):569-77 [10080601.001]
  • [Cites] Pediatr Hematol Oncol. 1999 May-Jun;16(3):267-70 [10326227.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2128-36 [17673902.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1389-98 [17768113.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2007;:453-9 [18024664.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1106-11 [18309945.001]
  • [Cites] Blood. 2008 May 1;111(9):4477-89 [18285545.001]
  • [Cites] Med Pediatr Oncol. 1989;17(6):477-84 [2586362.001]
  • [Cites] Leukemia. 1999 Mar;13(3):335-42 [10086723.001]
  • [Cites] Leukemia. 2000 Feb;14(2):232-7 [10673738.001]
  • [Cites] Blood. 2000 Mar 1;95(5):1588-93 [10688812.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):947-55 [10694543.001]
  • [Cites] Br J Haematol. 2000 Apr;109(1):13-23 [10848777.001]
  • [Cites] Br J Cancer. 2000 Jul;83(1):91-4 [10883674.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(15):2836-42 [10920131.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1289-94 [11106118.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2196-204 [11187911.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2234-9 [11187914.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2240-6 [11187915.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2257-66 [11187917.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2267-75 [11187918.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2276-85 [11187919.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2286-94 [11187920.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2295-306 [11187921.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2307-20 [11187922.001]
  • [Cites] Br J Haematol. 2001 Jan;112(1):109-17 [11225603.001]
  • [Cites] Med Pediatr Oncol. 2001 May;36(5):525-35 [11340607.001]
  • [Cites] Med Pediatr Oncol. 2001 May;36(5):536-40 [11340608.001]
  • [Cites] Leukemia. 2001 Jun;15(6):963-70 [11417484.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11592-7 [11553769.001]
  • [Cites] Lancet Oncol. 2001 Jul;2(7):429-36 [11905737.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Blood. 2002 Jul 15;100(2):427-34 [12091332.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1972-6 [12200354.001]
  • [Cites] Pharmacogenetics. 2002 Nov;12(8):605-11 [12439220.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1074-81 [12637473.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1195-204 [12663705.001]
  • [Cites] Blood. 2003 May 15;101(10):3862-7 [12531808.001]
  • [Cites] J Clin Oncol. 2003 Jun 1;21(11):2123-37 [12775738.001]
  • [Cites] Leukemia. 2004 Jan;18(1):120-5 [14586477.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2675-80 [15102670.001]
  • [Cites] Int J Hematol. 2004 Apr;79(3):229-34 [15168589.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2510-1 [15197216.001]
  • [Cites] Blood. 2004 Aug 1;104(3):822-8 [15090454.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1581-6 [15356657.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] J Clin Oncol. 1985 Apr;3(4):532-8 [2984346.001]
  • [Cites] Blood. 1987 Nov;70(5):1412-7 [2822173.001]
  • [Cites] Cancer. 1988 Oct 1;62(7):1364-70 [3046737.001]
  • [Cites] N Engl J Med. 1989 Jul 20;321(3):136-42 [2787477.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):432-7 [1999712.001]
  • [Cites] N Engl J Med. 1991 Dec 12;325(24):1682-7 [1944468.001]
  • [Cites] J Clin Oncol. 1992 Jan;10(1):156-63 [1309379.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):209-17 [8426196.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1039-45 [8388919.001]
  • [Cites] Leukemia. 1993 Dec;7(12):1975-86 [8255096.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1680-4 [7564509.001]
  • [Cites] Leukemia. 1996 Jan;10(1):27-31 [8558933.001]
  • (PMID = 19072983.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-31; United States / NCI NIH HHS / CA / P30 CA021765-31
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] L36H50F353 / Podophyllotoxin
  • [Number-of-references] 99
  • [Other-IDs] NLM/ NIHMS135594; NLM/ PMC2767267
  •  go-up   go-down


74. Rau T, Erney B, Göres R, Eschenhagen T, Beck J, Langer T: High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin Pharmacol Ther; 2006 Nov;80(5):468-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.
  • Subsequently, we assessed the association of polymorphisms with the methotrexate plasma concentrations in 44 pediatric patients with acute lymphoblastic leukemia (ALL) (29 male and 15 female patients; mean age, 6.8+/-4.8 years).
  • [MeSH-major] Membrane Transport Proteins / genetics. Methotrexate / pharmacokinetics. Methotrexate / therapeutic use. Multidrug Resistance-Associated Proteins / genetics. Polymorphism, Genetic / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy


75. Alexiou GA, Moschovi M, Georgoulis G, Neroutsou R, Stefanaki K, Sfakianos G, Prodromou N: Anaplastic oligodendrogliomas after treatment of acute lymphoblastic leukemia in children: report of 2 cases. J Neurosurg Pediatr; 2010 Feb;5(2):179-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic oligodendrogliomas after treatment of acute lymphoblastic leukemia in children: report of 2 cases.
  • Radiation-induced brain tumors are suggested to be the late complication of acute lymphoblastic leukemia (ALL) treatment.
  • The authors present 2 cases of pediatric anaplastic oligodendroglioma after treatment of ALL.
  • [MeSH-major] Brain Neoplasms / etiology. Oligodendroglioma / etiology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Radiotherapy / adverse effects


76. Ashokkumar C, Gupta A, Sun Q, Higgs BW, Ningappa M, Snyder S, Johnson M, Mazariegos G, Soltys K, Bond G, Abu-Elmagd K, Sindhi R: Proliferative alloresponse of T cytotoxic cells identifies rejection-prone children with small bowel transplantation. Transplantation; 2010 Jun 15;89(11):1371-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: More than 60% children with small bowel transplantation (SBTx) experience acute cellular rejection.
  • Rejectors were defined as those who experienced biopsy-proven acute cellular rejection within 60 days of the assay.
  • Significantly higher counts were observed for all proliferated CFSE(low) T-cell subsets among rejectors, compared with nonrejectors.
  • [MeSH-minor] Acute Disease. Animals. Cell Division. Child, Preschool. Coculture Techniques. Flow Cytometry. Globulins. Humans. Infant. Lymphocyte Culture Test, Mixed. Rabbits

  • Genetic Alliance. consumer health - Transplantation.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20458270.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Globulins
  •  go-up   go-down


77. Yang C, Sodian R, Fu P, Lüders C, Lemke T, Du J, Hübler M, Weng Y, Meyer R, Hetzer R: In vitro fabrication of a tissue engineered human cardiovascular patch for future use in cardiovascular surgery. Ann Thorac Surg; 2006 Jan;81(1):57-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The scaffold was seeded with pediatric aortic cells.
  • The cell-seeded patch constructs were placed in a self-developed bioreactor for 7 days to observe potential tissue formation under dynamic cell culture conditions.
  • As a control, cell-seeded scaffolds were not conditioned in the bioreactor system.
  • [MeSH-minor] Aorta / cytology. Biomechanical Phenomena. Bioreactors. Cell Division. Cells, Cultured / cytology. Cells, Cultured / metabolism. Child. Collagen / biosynthesis. Elastin / biosynthesis. Extracellular Matrix / metabolism. Forecasting. Humans. Implants, Experimental. Materials Testing. Polyesters. Pulsatile Flow. Rheology

  • MedlinePlus Health Information. consumer health - Heart Surgery.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2006 Jan;81(1):64 [16368336.001]
  • (PMID = 16368335.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biocompatible Materials; 0 / Polyesters; 0 / poly(4-hydroxybutanoate); 9007-34-5 / Collagen; 9007-58-3 / Elastin
  •  go-up   go-down


78. Mitsui T, Mori T, Fujita N, Inada H, Horibe K, Tsurusawa M, Lymphoma Committee, Japanese Pediatric Leukemia/Lymphoma Study Group: Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan. Pediatr Blood Cancer; 2009 May;52(5):591-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan.
  • BACKGROUND AND PROCEDURE: To assess the clinical course with response to second-line treatment and to evaluate the role of hematopoietic stem cell transplantation (SCT) in children with relapsed or primary refractory lymphoblastic lymphoma (LBL), we analyzed data of 48 patients with relapsed/primary refractory diseases among 260 LBL patients identified in a national survey of 1996-2004.
  • Univariate analysis identified two features (relapse within 12 months, T cell phenotype) as significant variables that predicted poor survival.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19156862.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


79. Meier M, den Boer ML, Meijerink JP, Broekhuis MJ, Passier MM, van Wering ER, Janka-Schaub GE, Pieters R: Differential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia. Leukemia; 2006 Aug;20(8):1377-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia.
  • The T-lineage phenotype of childhood acute lymphoblastic leukaemia (ALL) is associated with an increased relapse-risk and in vitro resistance to drugs as compared to a precursor B phenotype.
  • We demonstrate in our study that the expression of total p73 mRNA was higher in childhood T-ALL compared to controls (P=0.004).
  • Our results suggest that childhood T-ALL is associated with a high expression of DeltaTA-p73.
  • [MeSH-major] DNA-Binding Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Nuclear Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Cell Lineage. Child. Child, Preschool. DNA Methylation. Drug Resistance, Neoplasm. Genes, Tumor Suppressor. Humans. Infant. Loss of Heterozygosity. Protein Isoforms. RNA, Messenger / analysis. Tumor Suppressor Proteins

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791269.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  •  go-up   go-down


80. Doi T, Puri P, Bannigan J, Thompson J: Disruption of noncanonical Wnt/CA2+ pathway in the cadmium-induced omphalocele in the chick model. J Pediatr Surg; 2010 Aug;45(8):1645-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Noncanonical Wnt/Ca(2+) pathway has been implicated in regulating embryogenesis by controlling cell movement and adhesion.
  • CONCLUSION: Downregulation of Wnt11, PKCalpha, and CaMKII gene expression during the narrow window of early embryogenesis may cause VBWD, interfering with cell movement and adhesion, disrupting Wnt/Ca(2+) pathway.
  • [MeSH-minor] Animals. Calcium-Calmodulin-Dependent Protein Kinase Type 2 / drug effects. Calcium-Calmodulin-Dependent Protein Kinase Type 2 / genetics. Calcium-Calmodulin-Dependent Protein Kinase Type 2 / physiology. Cell Movement / genetics. Cell Movement / physiology. Chick Embryo. Disease Models, Animal. Down-Regulation. Embryonic Development / drug effects. Embryonic Development / genetics. Embryonic Development / physiology. Enzyme Activation / drug effects. Enzyme Activation / physiology. Gene Expression Regulation, Developmental / physiology. Humans. Protein Kinase C / drug effects. Protein Kinase C / metabolism

  • Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20713214.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Wnt Proteins; 0 / Wnt11 protein, human; 00BH33GNGH / Cadmium; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinase Type 2; SY7Q814VUP / Calcium
  •  go-up   go-down


81. Teachey DT, Greiner R, Seif A, Attiyeh E, Bleesing J, Choi J, Manno C, Rappaport E, Schwabe D, Sheen C, Sullivan KE, Zhuang H, Wechsler DS, Grupp SA: Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome. Br J Haematol; 2009 Apr;145(1):101-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome.
  • We hypothesized that sirolimus, an mTOR inhibitor, may be effective in patients with autoimmune lymphoproliferative syndrome (ALPS) and treated patients who were intolerant to or failed other therapies.
  • Four patients were treated for autoimmune cytopenias; all had a rapid complete or near complete response.
  • Two patients were treated for autoimmune arthritis and colitis, demonstrating marked improvement.
  • Three patients had complete resolution of lymphadenopathy and splenomegaly and all patients had a reduction in double negative T cells, a population hallmark of the disease.
  • Based on these significant responses, we recommend that sirolimus be considered as second-line therapy for patients with steroid-refractory disease.
  • [MeSH-major] Anemia, Hemolytic, Autoimmune / drug therapy. Immunosuppressive Agents / therapeutic use. Sirolimus / therapeutic use
  • [MeSH-minor] Child. Child, Preschool. Drug Administration Schedule. Follow-Up Studies. Humans. Infant. Male. Positron-Emission Tomography. Radiography

  • Genetic Alliance. consumer health - Autoimmune Lymphoproliferative Syndrome.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Clin North Am. 2000 Dec;47(6):1291-310 [11130997.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2466-73 [11588044.001]
  • [Cites] Cell Death Differ. 2003 Jan;10(1):124-33 [12655301.001]
  • [Cites] Science. 1995 Mar 10;267(5203):1449-56 [7533326.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1341-8 [9028957.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2828-35 [15572590.001]
  • [Cites] Curr Probl Cancer. 2008 Jul-Aug;32(4):161-77 [18655914.001]
  • [Cites] Blood. 2006 Sep 15;108(6):1965-71 [16757690.001]
  • [Cites] J Immunol. 2006 Dec 15;177(12):8338-47 [17142730.001]
  • [Cites] J Am Soc Nephrol. 2007 Mar;18(3):1007-18 [17287424.001]
  • [Cites] Drug News Perspect. 2007 May;20(4):260-2 [17637938.001]
  • [Cites] Blood. 2008 Jan 15;111(2):705-14 [17925488.001]
  • [Cites] Immunol Rev. 2008 Jun;223:371-90 [18613848.001]
  • [Cites] Br J Haematol. 2005 May;129(4):534-8 [15877736.001]
  • (PMID = 19208097.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / L40 CA110867; United States / NCI NIH HHS / CA / L40 CA110867-03; United States / NIAID NIH HHS / AI / N01 AI030070; United States / NIAID NIH HHS / AI / N01-AI-30070
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS173592; NLM/ PMC2819393
  •  go-up   go-down


82. Wu P, Feng K, Li J, Xie Z, Xue P, Cai T, Cui Z, Chen X, Hou J, Zhang J, Yang F: Discovery and identification of potential biomarkers of pediatric acute lymphoblastic leukemia. Proteome Sci; 2009 Mar 16;7:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discovery and identification of potential biomarkers of pediatric acute lymphoblastic leukemia.
  • BACKGROUND: Acute lymphoblastic leukemia (ALL) is a common form of cancer in children.
  • Noninvasive biomarkers for the early diagnosis of pediatric ALL are urgently needed.
  • The aim of this study was to discover potential protein biomarkers for pediatric ALL.
  • METHODS: Ninety-four pediatric ALL patients and 84 controls were randomly divided into a "training" set (45 ALL patients, 34 healthy controls) and a test set (49 ALL patients, 30 healthy controls and 30 pediatric acute myeloid leukemia (AML) patients).
  • RESULTS: A total of 7 protein peaks (9290 m/z, 7769 m/z, 15110 m/z, 7564 m/z, 4469 m/z, 8937 m/z, 8137 m/z) were found with differential expression levels in the sera of pediatric ALL patients and controls using SELDI-TOF-MS and then analyzed by BPS to construct a classification model in the "training" set.
  • Two candidate protein peaks (7769 and 9290 m/z) were found to be down-regulated in ALL patients, where these were identified as platelet factor 4 (PF4) and pro-platelet basic protein precursor (PBP).
  • CONCLUSION: Platelet factor (PF4), connective tissue activating peptide III (CTAP-III) and two fragments of C3a may be potential protein biomarkers of pediatric ALL and used to distinguish pediatric ALL patients from healthy controls and pediatric AML patients.
  • Further studies with additional populations or using pre-diagnostic sera are needed to confirm the importance of these findings as diagnostic markers of pediatric ALL.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2006 Apr 1;106(7):1587-94 [16518825.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):311-8 [10917544.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17041-6 [16286641.001]
  • [Cites] Leukemia. 2005 Oct;19(10):1713-8 [16136170.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1003-7 [15827132.001]
  • [Cites] Br J Cancer. 2005 Mar 14;92(5):895-905 [15726105.001]
  • [Cites] Hepatology. 2005 Jan;41(1):40-7 [15690480.001]
  • [Cites] Leukemia. 1997 Oct;11(10):1690-5 [9324290.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2328-35 [9116276.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] Cancer. 1995 Dec 15;76(12):2393-417 [8625065.001]
  • [Cites] N Engl J Med. 1995 Jun 15;332(24):1618-30 [7753142.001]
  • [Cites] Blood. 1993 Jul 15;82(2):343-62 [8329694.001]
  • [Cites] J Immunol. 2004 Jul 15;173(2):747-54 [15240660.001]
  • [Cites] Proteomics. 2006 May;6(9):2865-73 [16586433.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Novartis Found Symp. 2004;256:173-84; discussion 184-8, 259-69 [15027490.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12343-8 [14523236.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Sep 12;309(1):18-25 [12943657.001]
  • [Cites] BJU Int. 2003 Aug;92(3):223-5 [12887471.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):267-79 [12781425.001]
  • [Cites] Mol Cell Proteomics. 2003 Feb;2(2):107-16 [12644570.001]
  • [Cites] Semin Immunol. 2003 Feb;15(1):15-21 [12495637.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 16;94(20):1576-8 [12381711.001]
  • [Cites] Clin Chem. 2002 Oct;48(10):1835-43 [12324514.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2541-52 [12171882.001]
  • [Cites] J Immunol. 2002 Jul 15;169(2):770-7 [12097379.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3609-14 [12097261.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Transfus Med. 2001 Dec;11(6):403-17 [11851938.001]
  • [Cites] Immunol Rev. 2001 Apr;180:35-48 [11414361.001]
  • [Cites] Curr Opin Rheumatol. 2001 May;13(3):202-8 [11333349.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1491-502 [11290567.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):287-92 [16404431.001]
  • (PMID = 19291297.001).
  • [ISSN] 1477-5956
  • [Journal-full-title] Proteome science
  • [ISO-abbreviation] Proteome Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2662805
  •  go-up   go-down


83. Cooper TM: Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Ther Clin Risk Manag; 2007 Dec;3(6):1135-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
  • T-cell malignancies have distinct biochemical, immunologic, and clinical features which set them apart from non-T-cell malignancies.
  • In the past, T-cell leukemia portended a worse prognosis than leukemia of B-cell origin.
  • Cure rates have improved with intensification of therapy and advanced understanding of the molecular genetics of T-cell malignancies.
  • Further advances in the treatment of T-cell leukemia will require the development of novel agents that can target specific malignancies without a significant increase in toxicity.
  • Clinical and pharmacokinetic investigations have established that nelarabine is active as a single agent which has led to exploration of an expanded role in the treatment of T-cell hematologic malignances.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3376-82 [15908649.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5329-35 [17000665.001]
  • [Cites] J Immunol. 1990 Jan 15;144(2):485-91 [2104895.001]
  • [Cites] Leukemia. 1990 Nov;4(11):739-44 [2232884.001]
  • [Cites] Cancer Res. 1990 Mar 15;50(6):1817-21 [2306735.001]
  • [Cites] Blood. 1988 Dec;72(6):1891-7 [3058229.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Oct;75(10):5011-4 [311004.001]
  • [Cites] Lancet. 1975 May 3;1(7914):1010-3 [48676.001]
  • [Cites] J Biol Chem. 1968 Aug 25;243(16):4298-304 [5684726.001]
  • [Cites] Biochem J. 1983 Sep 15;214(3):711-8 [6312962.001]
  • [Cites] Blood. 1983 Apr;61(4):660-6 [6600944.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1517-24 [7533664.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3352-6 [7614470.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3122-33 [7949185.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):740-7 [8151317.001]
  • [Cites] Leukemia. 1993 Aug;7(8):1261-7 [8350627.001]
  • [Cites] Blood. 1993 Apr 15;81(8):2110-7 [8471769.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):18-24 [8558195.001]
  • [Cites] Blood. 1998 Feb 1;91(3):735-46 [9446631.001]
  • [Cites] J Clin Invest. 1978 May;61(5):1405-9 [96138.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2107-13 [9815603.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3607-15 [9817282.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4937-43 [10519407.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):995-1003 [10694549.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2196-204 [11187911.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2142-52 [11304766.001]
  • [Cites] Leuk Lymphoma. 2001 Apr;41(3-4):321-31 [11378544.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3100-5 [12036920.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Dec;15(4):741-56 [12617874.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1842-8 [12750168.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3396-403 [15908652.001]
  • (PMID = 18516261.001).
  • [ISSN] 1176-6336
  • [Journal-full-title] Therapeutics and clinical risk management
  • [ISO-abbreviation] Ther Clin Risk Manag
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2387290
  • [Keywords] NOTNLM ; 9-β-D-arabinofuranosylguanine / T-cell acute lymphoblastic leukemia / nelarabine
  •  go-up   go-down


84. Nagata K, Masumoto K, Uesugi T, Yamamoto S, Yoshizaki K, Fukumoto S, Nonaka K, Taguchi T: Effect of insulin-like-growth factor and its receptors regarding lung development in fetal mice. Pediatr Surg Int; 2007 Oct;23(10):953-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All cultures were investigated by immunohistochemistry, using the antibodies of thyroid transcription factor (TTF)-1, prosurfactant protein (proSp)-C, alpha smooth muscle actin (alpha-SMA), and anti-proliferating cell nuclear antigen (PCNA).

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Rev Respir Dis. 1987 Oct;136(4):947-50 [3662245.001]
  • [Cites] Mech Dev. 2003 Mar;120(3):349-61 [12591604.001]
  • [Cites] J Histochem Cytochem. 2005 Jun;53(6):735-44 [15928322.001]
  • [Cites] J Pediatr Surg. 1998 Oct;33(10):1476-9 [9802794.001]
  • [Cites] Biotechniques. 1997 Jan;22(1):176-81 [8994665.001]
  • [Cites] Pediatr Res. 1994 May;35(5):523-9 [7520565.001]
  • [Cites] J Pediatr Surg. 1993 Mar;28(3):471-5; discussion 476-7 [8468664.001]
  • [Cites] J Pediatr Surg. 1999 Nov;34(11):1652-7 [10591563.001]
  • [Cites] Am J Respir Cell Mol Biol. 1996 Jan;14(1):61-9 [8534487.001]
  • [Cites] Endocrinology. 2006 Dec;147(12):5584-91 [16959842.001]
  • [Cites] Mech Dev. 2000 Mar 15;92(1):55-81 [10704888.001]
  • [Cites] Cell. 1993 Oct 8;75(1):73-82 [8402902.001]
  • [Cites] Pediatr Surg Int. 1999;15(3-4):175-9 [10370016.001]
  • [Cites] JAMA. 1994 Feb 2;271(5):382-4 [8054005.001]
  • [Cites] Dev Dyn. 2006 Aug;235(8):2040-50 [16691571.001]
  • [Cites] J Pediatr Surg. 2005 Mar;40(3):457-63 [15793718.001]
  • [Cites] Cell. 1993 Oct 8;75(1):59-72 [8402901.001]
  • [Cites] J Pediatr Surg. 2004 Mar;39(3):313-8; discussion 313-8 [15017544.001]
  • [Cites] Histopathology. 2006 Apr;48(5):588-95 [16623785.001]
  • [Cites] Nature. 1994 Dec 1;372(6505):464-7 [7984240.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Feb;28(2):159-69 [12540483.001]
  • [Cites] J Histochem Cytochem. 1996 Oct;44(10):1183-93 [8813084.001]
  • [Cites] Curr Opin Pediatr. 2002 Aug;14(4):486-90 [12130916.001]
  • (PMID = 17653731.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Somatomedin; 0 / Somatomedins
  •  go-up   go-down


85. Liu Y, Chen J, Tang J, Ni S, Xue H, Pan C: Cost of childhood acute lymphoblastic leukemia care in Shanghai, China. Pediatr Blood Cancer; 2009 Oct;53(4):557-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost of childhood acute lymphoblastic leukemia care in Shanghai, China.
  • BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common and curable malignant pediatric disease in children.
  • Here, we analyzed the overall costs for pediatric ALL therapies and their constitutive elements.
  • Average overall costs for childhood ALL in this study were less than US $11,000, with reasonable clinical results.
  • [MeSH-major] Health Care Costs. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


86. Dakka N, Bellaoui H, Bouzid N, Khattab M, Bakri Y, Benjouad A: CD10 AND CD34 expression in childhood acute lymphoblastic leukemia in Morocco: clinical relevance and outcome. Pediatr Hematol Oncol; 2009 Jun;26(4):216-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10 AND CD34 expression in childhood acute lymphoblastic leukemia in Morocco: clinical relevance and outcome.
  • CD10 and CD34 expression in 86 Moroccan children with acute lymphoblastic leukemias (ALL) and the relevance to prognosis, diagnosis, and outcome during a 5-year follow-up were examined.
  • [MeSH-major] Antigens, CD34 / immunology. Biomarkers, Tumor / immunology. Neprilysin / immunology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19437324.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


87. Björklund E, Matinlauri I, Tierens A, Axelsson S, Forestier E, Jacobsson S, Ahlberg AJ, Kauric G, Mäntymaa P, Osnes L, Penttilä TL, Marquart H, Savolainen ER, Siitonen S, Torikka K, Mazur J, Porwit A: Quality control of flow cytometry data analysis for evaluation of minimal residual disease in bone marrow from acute leukemia patients during treatment. J Pediatr Hematol Oncol; 2009 Jun;31(6):406-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality control of flow cytometry data analysis for evaluation of minimal residual disease in bone marrow from acute leukemia patients during treatment.
  • Low levels of leukemia cells in the bone marrow, minimal residual disease (MRD), are considered to be a powerful indicator of treatment response in acute lymphatic leukemia (ALL).
  • A Nordic quality assurance program, aimed on standardization of the flow cytometry MRD analysis, has been established before implementation of MRD at cutoff level 10 as one of stratifying parameters in next Nordic Society of Pediatric Hematology and Oncology (NOPHO) treatment program for ALL.
  • The concordance was higher in precursor B as compared with T-cell ALL.
  • [MeSH-major] Flow Cytometry / standards. Neoplasm, Residual / diagnosis. Pathology, Clinical / standards. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19648789.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


88. Schwarz J, Korístek Z, Starý J, Zák P, Kozák T, Marková J, Michalová K, Dvoráková D, Mayer J, Cetkovský P: [Therapy of acute promyelocytic leukemia in Czechia: results and analysis of prognostic factors]. Vnitr Lek; 2008 Jul-Aug;54(7-8):757-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy of acute promyelocytic leukemia in Czechia: results and analysis of prognostic factors].
  • We have retrospectively evaluated a cohort of 144 patients (including 17 pediatric ones) with de novo acute promyelocytic leukemia registered in databases of institutions cooperating within the CELL group (The Czech Leukemia Study Group for Life).
  • [MeSH-major] Leukemia, Promyelocytic, Acute / drug therapy

  • Genetic Alliance. consumer health - Acute Promyelocytic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18780575.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


89. Hansson F, Toporski J, Månsson R, Johansson B, Norén-Nyström U, Jacobsen SE, Wiebe T, Larsson M, Sigvardsson M, Castor A: Exit of pediatric pre-B acute lymphoblastic leukaemia cells from the bone marrow to the peripheral blood is not associated with cell maturation or alterations in gene expression. Mol Cancer; 2008;7:67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exit of pediatric pre-B acute lymphoblastic leukaemia cells from the bone marrow to the peripheral blood is not associated with cell maturation or alterations in gene expression.
  • BACKGROUND: Childhood pre-B acute lymphoblastic leukemia (ALL) is a bone marrow (BM) derived disease, which often disseminates out of the BM cavity, where malignant cells to a variable degree can be found circulating in the peripheral blood (PB).
  • In addition, the cell sorting procedure revealed that in 2 out of five investigated patients, a significant fraction of the malignant cells had matured beyond the pre-B cell stage.
  • [MeSH-major] Blood Cells / metabolism. Bone Marrow Cells / metabolism. Gene Expression. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Cell Differentiation. Cell Lineage. Cell Movement. Child. Gene Expression Profiling. Humans. Immunoglobulins / metabolism. In Situ Hybridization, Fluorescence. Stromal Cells / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Genes Dev. 2000 Aug 15;14(16):1983-91 [10950862.001]
  • [Cites] J Clin Invest. 2000 Aug;106(4):511-21 [10953026.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19069-74 [16354839.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2223-33 [11187913.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2247-56 [11187916.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2267-75 [11187918.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):954-8 [12087404.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2690-6 [15251979.001]
  • [Cites] J Exp Med. 1996 Dec 1;184(6):2217-29 [8976177.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4150-66 [9834220.001]
  • [Cites] Cell. 2005 Apr 22;121(2):295-306 [15851035.001]
  • [Cites] Nat Med. 2005 Jun;11(6):630-7 [15908956.001]
  • (PMID = 18694513.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501838
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulins; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2525657
  •  go-up   go-down


90. Quigley DI, Wolff DJ: Pediatric T-cell acute lymphoblastic leukemia with aberrations of both MLL loci. Cancer Genet Cytogenet; 2006 Jul 1;168(1):77-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric T-cell acute lymphoblastic leukemia with aberrations of both MLL loci.
  • Translocations involving the MLL gene at 11q23 have been implicated in acute lymphoblastic leukemia (ALL), as well as acute myeloid leukemia (AML).
  • Such translocations result in gain of function fusion proteins that drive cell proliferation.
  • Except in cases of T-cell ALL, MLL rearrangement is typically associated with a poor prognosis.
  • We report a case of T-cell ALL with a t(11;19)(q23;p13.3) and deletion of the other chromosome 11 homolog at band q23.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Gene Deletion. Leukemia-Lymphoma, Adult T-Cell / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Translocation, Genetic / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16772125.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


91. Bianchini L, Maire G, Pedeutour F, Groupe Francophone de Cytogénétique Oncologique: [From cytogenetics to cytogenomics of dermatofibrosarcoma protuberans family of tumors]. Bull Cancer; 2007 Feb;94(2):179-89
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rings have been mainly observed in adults whereas translocations have been reported in all pediatric cases.
  • It is also present in variant forms of DP such as giant cell fibroblastoma, Bednar tumor, adult superficial fibrosarcoma and the granular cell variant of DP demonstrating that these tumors are not distinct entities but morphological variants of DP.

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337387.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / COLIA1-PDGFB fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


92. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P, Larson RA, Parsons S, Seidenfeld J, Weisdorf D, McCarthy PL Jr: The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. Biol Blood Marrow Transplant; 2005 Nov;11(11):823-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review.
  • Evidence supporting the role of hematopoietic stem cell transplantation (SCT) in the therapy of acute lymphoblastic leukemia (ALL) in children is presented and critically evaluated in this systematic evidence-based review.
  • Treatment recommendations based on the evidence are presented in a table in this review (Summary of Treatment Recommendations Made by the Expert Panel for Pediatric Acute Lymphoblastic Leukemia) and were reached unanimously by a panel of ALL experts.
  • The priority areas of needed future research in pediatric ALL are unrelated marrow or blood donor versus unrelated cord blood donor allogeneic SCT; alternative, nonfamily allogeneic donor versus autologous SCT; better methods for identifying high-relapse-risk patients; assessments of the effect of current chemotherapy regimens on early relapse; and use of pre-SCT detection of minimal residual disease to predict post-SCT outcomes.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Evidence-Based Medicine. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16275588.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 92
  •  go-up   go-down


93. Silvestroni A, Jewell KA, Lin WJ, Connelly JE, Ivancic MM, Tao WA, Rajagopal L: Identification of serine/threonine kinase substrates in the human pathogen group B streptococcus. J Proteome Res; 2009 May;8(5):2563-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of serine/threonine kinase substrates in the human pathogen group B streptococcus.
  • All living organisms respond to changes in their internal and external environment for their survival and existence.
  • Signaling is primarily achieved through reversible phosphorylation of proteins in both prokaryotes and eukaryotes.
  • A change in the phosphorylation state of a protein alters its function to enable the control of cellular responses.
  • A number of serine/threonine kinases regulate the cellular responses of eukaryotes.
  • Although common in eukaryotes, serine/threonine kinases have only recently been identified in prokaryotes.
  • We have described that the human pathogen Group B Streptococcus (GBS, Streptococcus agalactiae) encodes a single membrane-associated, serine/threonine kinase (Stk1) that is important for virulence of this bacterium.
  • In this study, we used a combination of phosphopeptide enrichment and mass spectrometry to enrich and identify serine (S) and threonine (T) phosphopeptides of GBS.
  • A comparison of S/T phosphopeptides identified from the Stk1 expressing strains to the isogenic stk1 mutant indicates that 10 proteins are potential substrates of the GBS Stk1 enzyme.
  • Some of these proteins are phosphorylated by Stk1 in vitro and a site-directed substitution of the phosphorylated threonine to an alanine abolished phosphorylation of an Stk1 substrate.
  • Collectively, these studies provide a novel approach to identify serine/threonine kinase substrates for insight into their signaling in human pathogens like GBS.

  • Hazardous Substances Data Bank. (L)-ALANINE .
  • Hazardous Substances Data Bank. L-Threonine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bacteriol. 1996 Aug;178(16):4759-64 [8759835.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9431-6 [10920208.001]
  • [Cites] FEBS J. 2005 Mar;272(5):1243-54 [15720398.001]
  • [Cites] Microbiology. 2005 Apr;151(Pt 4):1159-67 [15817783.001]
  • [Cites] Microbiology. 2005 May;151(Pt 5):1381-93 [15870448.001]
  • [Cites] Mol Microbiol. 2005 Jun;56(5):1329-46 [15882424.001]
  • [Cites] Genes Dev. 2005 Jul 15;19(14):1692-704 [15985609.001]
  • [Cites] Nat Methods. 2005 Aug;2(8):591-8 [16094384.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13950-5 [16172379.001]
  • [Cites] Biosci Rep. 2005 Feb-Apr;25(1-2):33-44 [16222418.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Nov;6(11):862-71 [16227976.001]
  • [Cites] Proteomics. 2005 Nov;5(16):4052-61 [16196093.001]
  • [Cites] J Mol Microbiol Biotechnol. 2005;9(3-4):125-31 [16415586.001]
  • [Cites] Annu Rev Biochem. 2000;69:183-215 [10966457.001]
  • [Cites] FEBS Lett. 2000 Sep 29;482(1-2):139-43 [11018537.001]
  • [Cites] Microb Comp Genomics. 2000;5(2):103-20 [11087177.001]
  • [Cites] Microbes Infect. 2001 Apr;3(5):417-24 [11369279.001]
  • [Cites] FEMS Microbiol Lett. 2001 Jun 12;200(1):79-84 [11410353.001]
  • [Cites] Microbiology. 2001 Aug;147(Pt 8):2307-14 [11496007.001]
  • [Cites] FEMS Microbiol Lett. 2002 Jan 2;206(1):1-8 [11786249.001]
  • [Cites] Eur J Biochem. 2002 Feb;269(4):1078-85 [11856348.001]
  • [Cites] Nat Rev Drug Discov. 2002 Apr;1(4):309-15 [12120282.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12391-6 [12200547.001]
  • [Cites] Mol Microbiol. 2002 Sep;45(6):1499-513 [12354221.001]
  • [Cites] Mini Rev Med Chem. 2001 May;1(1):43-55 [12369990.001]
  • [Cites] Mol Microbiol. 2002 Oct;46(2):571-86 [12406230.001]
  • [Cites] Science. 2002 Dec 6;298(5600):1912-34 [12471243.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):14429-41 [12562757.001]
  • [Cites] J Mol Biol. 2004 Jan 9;335(2):655-63 [14672671.001]
  • [Cites] Mol Cell Proteomics. 2004 Mar;3(3):279-86 [14729942.001]
  • [Cites] Infect Immun. 2004 Apr;72(4):2434-7 [15039376.001]
  • [Cites] Mol Microbiol. 2004 Jun;52(6):1691-702 [15186418.001]
  • [Cites] Science. 2004 Jun 18;304(5678):1800-4 [15155913.001]
  • [Cites] Infect Immun. 1991 Jan;59(1):204-10 [1702759.001]
  • [Cites] Infect Immun. 1991 Aug;59(8):2638-44 [1855984.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):718-22 [1731345.001]
  • [Cites] Nature. 1993 Feb 25;361(6414):730-2 [8441468.001]
  • [Cites] Microb Ecol. 2006 Feb;51(2):166-76 [16435167.001]
  • [Cites] J Med Chem. 2006 Mar 9;49(5):1658-67 [16509582.001]
  • [Cites] J Bacteriol. 2006 Mar;188(6):2096-105 [16513739.001]
  • [Cites] Eukaryot Cell. 2006 Mar;5(3):457-68 [16524901.001]
  • [Cites] J Mol Biol. 2006 Apr 14;357(5):1351-72 [16487973.001]
  • [Cites] Proteomics. 2006 Jul;6(14):4047-56 [16791829.001]
  • [Cites] J Biol Chem. 1994 Nov 25;269(47):29855-9 [7961979.001]
  • [Cites] Mol Microbiol. 2006 Nov;62(4):941-57 [17005013.001]
  • [Cites] J Biol Chem. 2006 Dec 29;281(52):40107-13 [17068335.001]
  • [Cites] Brief Funct Genomic Proteomic. 2006 Feb;4(4):363-76 [17202127.001]
  • [Cites] J Bacteriol. 2007 Feb;189(4):1288-98 [17098892.001]
  • [Cites] Nat Methods. 2007 Mar;4(3):231-7 [17293869.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3508-13 [17360674.001]
  • [Cites] Mol Biosyst. 2007 Apr;3(4):275-86 [17372656.001]
  • [Cites] Mol Cell Proteomics. 2007 Apr;6(4):697-707 [17218307.001]
  • [Cites] Nat Cell Biol. 2007 Jul;9(7):797-803 [17558395.001]
  • [Cites] J Bacteriol. 2007 Aug;189(15):5574-81 [17545286.001]
  • [Cites] Mol Cell Proteomics. 2008 Jan;7(1):145-62 [17934212.001]
  • [Cites] Mol Cell Proteomics. 2008 Feb;7(2):299-307 [17938405.001]
  • [Cites] J Biol Chem. 2008 Jun 27;283(26):18099-112 [18442973.001]
  • [Cites] Proteomics. 2008 Sep;8(17):3486-93 [18668697.001]
  • [Cites] Mol Microbiol. 2008 Dec;70(6):1556-69 [19019154.001]
  • [Cites] Mol Microbiol. 2009 Mar;71(6):1477-95 [19170889.001]
  • [Cites] Trends Microbiol. 2000 May;8(5):238-44 [10785641.001]
  • [Cites] Mol Microbiol. 1996 May;20(3):593-603 [8736538.001]
  • (PMID = 19309132.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / AI070749-03; United States / NIAID NIH HHS / AI / R01 AI070749; United States / NIAID NIH HHS / AI / R56 AI070749; United States / NIAID NIH HHS / AI / R01 AI070749-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Phosphopeptides; 2ZD004190S / Threonine; EC 2.7.1.- / Stk1 protein, Streptococcus agalactiae; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; OF5P57N2ZX / Alanine
  • [Other-IDs] NLM/ NIHMS191961; NLM/ PMC2863997
  •  go-up   go-down


94. Pfeiffer M, Stanojevic S, Feuchtinger T, Greil J, Handgretinger R, Barbin K, Jung G, Martin D, Niethammer D, Lang P: Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation. Bone Marrow Transplant; 2005 Jul;36(2):91-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab mediates in vitro antileukemic activity in pediatric patients after allogeneic transplantation.
  • Relapse is a major problem after allogeneic transplantation in children with acute B-lineage lymphoblastic leukemias (ALL) and lymphomas and additional therapeutic strategies are needed to increase graft versus leukemia effects without inducing graft versus host disease (GvHD).
  • We studied the ability of rituximab to mediate antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) with effector cells and complement from patients who were transplanted with T-cell-depleted grafts from unrelated or mismatched related donors.
  • Highest lytic activity (ADCC) was observed against leukemia-derived MHH4 cells and Burkitt's lymphoma-derived Raji cells in the first months after transplantation, corresponding to the high percentage of regenerating CD56+ CD16+ cells.
  • Moreover, primary cryopreserved ALL-blasts from a pediatric patient were also efficiently lysed.
  • These findings encourage clinical trials on the use of rituximab for improving minimal residual disease control and relapse prevention after allogeneic high-risk transplantation in the small group of pediatric patients with CD20+ leukemias/lymphomas.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antibody-Dependent Cell Cytotoxicity / immunology. Antineoplastic Agents / pharmacology. Burkitt Lymphoma / immunology. Lymphoma, B-Cell / immunology
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Murine-Derived. Child. Child, Preschool. Complement System Proteins / immunology. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Mice. Rituximab. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908973.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 9007-36-7 / Complement System Proteins
  •  go-up   go-down


95. Haberler C, Laggner U, Slavc I, Czech T, Ambros IM, Ambros PF, Budka H, Hainfellner JA: Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: Lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype. Am J Surg Pathol; 2006 Nov;30(11):1462-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: Lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype.
  • Immunohistochemical lack of nuclear INI1 protein expression has been recently described as characteristic finding in atypical teratoid/rhabdoid tumors (AT/RTs), and has been suggested as useful marker to distinguish AT/RTs from other malignant pediatric central nervous system (CNS) tumors.
  • In this study, we examined a large series of malignant pediatric CNS tumors to determine the immunohistochemical expression of INI1 protein in different malignant pediatric tumor entities.
  • Archival paraffin-embedded biopsy specimens of 289 malignant pediatric CNS tumors including medulloblastomas, supratentorial primitive neuroectodermal tumors, glioblastomas, anaplastic astrocytomas, anaplastic ependymomas, choroid plexus carcinomas, germ cell tumors, and AT/RTs were analyzed immunohistochemically for expression of nuclear INI1 protein.
  • We conclude that INI1 protein analysis should be routinely performed in all malignant pediatric embryonal CNS tumors to detect cases with lack of INI1 protein, because patients with these tumors are likely to benefit from intensified treatment.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17063089.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / SMARCB1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


96. Aplenc R, Thompson J, Han P, La M, Zhao H, Lange B, Rebbeck T: Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res; 2005 Mar 15;65(6):2482-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia.
  • A significant portion of patients treated for pediatric acute lymphoblastic leukemia (ALL) relapse.
  • Methotrexate (MTX), which interrupts folate metabolism, is a mainstay of pediatric ALL therapy.
  • These data provide evidence that the MTHFR C677T polymorphism is a common genetic variant conferring a moderate relative risk and a high attributable risk for relapse in pediatric ALL patients.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Methotrexate / therapeutic use. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / enzymology


97. Jarrar M, Gaynon PS, Periclou AP, Fu C, Harris RE, Stram D, Altman A, Bostrom B, Breneman J, Steele D, Trigg M, Zipf T, Avramis VI: Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941). Pediatr Blood Cancer; 2006 Aug;47(2):141-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
  • PURPOSE: Re-induction outcomes vary for children with acute lymphoblastic leukemia (ALL) and marrow relapse.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Asparaginase / pharmacology. Asparagine / drug effects. Polyethylene Glycols / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ASPARAGINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16425271.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Conference; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / pegaspargase; 30IQX730WE / Polyethylene Glycols; 3KX376GY7L / Glutamic Acid; 7006-34-0 / Asparagine; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


98. Stephan H, Zakrzewski JL, Bölöni R, Grasemann C, Lohmann DR, Eggert A: Neurotrophin receptor expression in human primary retinoblastomas and retinoblastoma cell lines. Pediatr Blood Cancer; 2008 Feb;50(2):218-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurotrophin receptor expression in human primary retinoblastomas and retinoblastoma cell lines.
  • PROCEDURE: We analyzed TrkA, TrkB, TrkC, and p75 expression using semi-quantitative RT-PCR in 23 retinoblastomas and 8 retinoblastoma cell lines.
  • RESULTS: Almost all tumor samples and cell lines demonstrated high expression of all Trk receptors.
  • In contrast, p75 expression was substantially reduced in a subset of tumors and cell lines, in particular compared to its expression in normal retina.
  • [MeSH-minor] Age Factors. Apoptosis / physiology. Brain-Derived Neurotrophic Factor / pharmacology. Cell Growth Processes / drug effects. Cell Growth Processes / physiology. Cell Line, Tumor. Humans. Immunohistochemistry. Infant. Nerve Growth Factor / pharmacology. Nerve Growth Factors / biosynthesis. Nerve Growth Factors / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptor, Nerve Growth Factor / biosynthesis. Receptor, Nerve Growth Factor / genetics. Receptor, trkA / biosynthesis. Receptor, trkA / genetics. Receptor, trkB / biosynthesis. Receptor, trkB / genetics. Receptor, trkC / biosynthesis. Receptor, trkC / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Retinoblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17973327.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Brain-Derived Neurotrophic Factor; 0 / Nerve Growth Factors; 0 / RNA, Messenger; 0 / Receptor, Nerve Growth Factor; 0 / Receptors, Nerve Growth Factor; 9061-61-4 / Nerve Growth Factor; EC 2.7.10.1 / Receptor, trkA; EC 2.7.10.1 / Receptor, trkB; EC 2.7.10.1 / Receptor, trkC
  •  go-up   go-down


99. Graham DK, Salzberg DB, Kurtzberg J, Sather S, Matsushima GK, Keating AK, Liang X, Lovell MA, Williams SA, Dawson TL, Schell MJ, Anwar AA, Snodgrass HR, Earp HS: Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res; 2006 May 1;12(9):2662-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia.
  • To determine if Mer expression is ectopic in T-cell acute lymphoblastic leukemia (ALL) and potentially important in leukemogenesis, we analyzed Mer expression in normal human thymocytes and lymphocytes and in pediatric ALL patient samples.
  • Mer expression in 34 T-cell ALL (T-ALL) patient samples was evaluated by reverse transcription-PCR, and Mer protein expression in a separate cohort of 16 patient samples was assayed by flow cytometry and Western blot.
  • CONCLUSIONS: Transforming Mer signals may contribute to T-cell leukemogenesis, and abnormal Mer expression may be a novel therapeutic target in pediatric ALL therapy.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16675557.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082086; United States / NCI NIH HHS / CA / CA 68346; United States / NCI NIH HHS / CA / P30 CA46934; United States / NCI NIH HHS / CA / T32CA8608604
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / RNA, Neoplasm; EC 2.7.10.1 / MERTK protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


100. Kato I, Manabe A, Aoyama C, Kamiya T, Morimoto T, Matsufuji H, Suzuki K, Kitagawa Y, Hori T, Tsurusawa M, Kiyokawa N, Junichiro F, Hosoya R: Development of diffuse large B cell lymphoma during the maintenance therapy for B-lineage acute lymphoblastic leukemia. Pediatr Blood Cancer; 2007 Feb;48(2):230-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of diffuse large B cell lymphoma during the maintenance therapy for B-lineage acute lymphoblastic leukemia.
  • Non-Hodgkin lymphoma (NHL) is a very rare complication of acute lymphoblastic leukemia (ALL).
  • While he was receiving maintenance treatment 2 years and 9 months after the diagnosis of ALL, diffuse large B cell lymphoma (DLBL) was diagnosed from a biopsy of an abdominal mass.
  • [MeSH-major] Lymphoma, B-Cell / etiology. Lymphoma, Large B-Cell, Diffuse / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications






Advertisement